Annual Report • Nov 29, 2023
Annual Report
Open in ViewerOpens in native device viewer
Benchmark, the aquaculture biotechnology company, announces its full year audited results for the year ended 30 September 2023 (the "period").
| £m | FY 2023 | FY 2022 restated* |
% AER | % CER** |
|---|---|---|---|---|
| Revenue from continuing operations | 169.5 | 157.7 | 7% | 7% |
| Adjusted | ||||
| Adjusted EBITDA1 from continuing operations |
35.5 | 32.6 | 9% | 11% |
| Adjusted EBITDA from continuing operations excluding fair value uplift from biological assets |
35.6 | 31.0 | 15% | 16% |
| 2 Adjusted operating profit from continuing operations |
14.6 | 10.7 | 36% | 41% |
| Statutory | ||||
|---|---|---|---|---|
| Operating loss from continuing operations | (5.3) | (6.2) | 15% | 22% |
| Loss before tax from continuing operations | (12.7) | (21.4) | 41% | 44% |
| Loss for the period including discontinued operations | (21.6) | (30.5) | 29% | 31% |
| Basic loss per share (p) | (3.16) | (4.60) | 31% | |
| Net debt3 | (65.5) | (73.7) | ||
| Net debt excluding lease liabilities | (45.6) | (47.5) |
* 2022 figures have been restated to reflect changes to the ongoing continuing business during the year following the disposal of the tilapia business
** Constant exchange rate (CER) figures derived by retranslating current year figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and amortisation and impairment), before exceptional items including acquisition related items.
(2) Adjusted Operating Profit is operating loss before exceptional items including acquisition related items and amortisation of intangible assets excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
(4) Cash generated from operations after working capital and taxes as percentage of Adj. EBITDA
| Business Area Performance (continuing operations) £m |
FY 2023 | FY 2022 restated * |
% AER | % CER** |
|---|---|---|---|---|
| Revenue | ||||
| Genetics | 65.5 | 57.4 | 14% | 20% |
| Advanced Nutrition | 78.5 | 80.3 | (2%) | (7%) |
| Animal Health | 25.5 | 20.1 | 27% | 29% |
| Adjusted EBITDA1 | ||||
| Genetics | 15.7 | 17.4 | (10%) | (1%) |
| - excluding fair value movements in biological assets |
15.8 | 15.8 | 0% | 8% |
| Advanced Nutrition | 18.4 | 19.0 | (3%) | (8%) |
| Animal Health | 4.8 | 0.1 | 4,295% | 4,165% |
** Constant exchange rate (CER) figures derived by retranslating current year figures using previous year's foreign exchange rates (1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and amortisation and impairment), before exceptional items including acquisition related expenditure.
Advanced Nutrition – commercial focus and programme of efficiencies translate into business resilience and stronger market position
"We delivered good growth in revenue and Adjusted EBITDA, and increased cash conversion, despite challenging conditions in the global shrimp markets. This demonstrates the strength of our business and the agility of our organisation to adapt – mitigating the impact of a soft market and taking advantage of commercial opportunities to further consolidate our leading market position. The new financial year has also started well and in line with our expectations, with positive momentum in our three business areas.
"Since the end of FY20 when we completed the Group restructuring, we have been building a track record of growth and improved profitability, reflected by revenues and Adjusted EBITDA from continuing operations which have increased over this period by 61% and 128%, respectively.
"Benchmark is uniquely positioned in an industry that is structurally growing supported by attractive megatrends. With a clear strategy and an integrated commercial network covering the main aquaculture species, we have significant opportunity to deliver growth and shareholders returns. We will continue the execution of our strategy to realise the value inherent in our business for the benefit of all our stakeholders."
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a presentation for analysts and institutional investors on the day at 08.00 GMT (09.00 CET).
The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway. To register your interest, please contact [email protected]
A live webcast of the presentation will be available for analysts and investors to join remotely at the following link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20231129\_1
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers at 12.00 GMT (13:00 CET). The webcast is open to all existing and potential shareholders.
To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-29november2023
| Benchmark Holdings plc | Tel: 0114 240 9939 |
|---|---|
| Trond Williksen, CEO Septima Maguire, CFO Ivonne Cantu, Investor Relations |
|
| Deutsche Numis (Broker and NOMAD) | Tel: 020 7260 1000 |
| Freddie Barnfield, Duncan Monteith, Sher Shah | |
| MHP | Tel: 020 3128 8100 |
| Katie Hunt, Reg Hoare, Veronica Farah | [email protected] |
| About Benchmark |
Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability. We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out. Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com
2023 marks the third consecutive year of financial and strategic delivery following the Group restructuring and the appointment of a new management team in 2020. The new financial discipline and commercial focus implemented by our CEO and CFO are now well embedded in the Group and, together with our ongoing organisational change programme, are driving continued growth and strategic progress. Since 2020 Benchmark's revenue from continuing operations has grown from £105.4m (after adjusting for £0.2m revenue from the divested tilapia business) to £169m and Adjusted EBITDA has increased from £15.5m (after adjusting for loss of £1.1m from the divested tilapia business) to £35.5m, turning operating cashflow positive. In the same period, operating loss has reduced from £9.6m (after adjusting for loss of £1.2m from the divested tilapia business) to £5.3m, and total loss for the year has reduced from £31.9m to £21.6m.
We have a strong business with a capable organisation which is capitalising on the attractive megatrends in our industry, and which has proven its agility to adapt to the cyclicality in our end markets, taking every opportunity to further consolidate our leading market position.
The structural growth drivers in our industry are increasingly compelling. Aquaculture plays a crucial role in meeting the demand for seafood and represents a growing proportion of seafood consumption.
In addition, there are a number of exciting trends gaining momentum which are further driving the demand for innovative biotechnology solutions which are our focus. For instance, the increasing adoption of certification standards; the adoption of technological advancements, from automation to genetic improvements; the emergence of alternative feeds; and the increased use of data driven, AI enabled decision making are all aligned with and support Benchmark's future growth.
We continued our strategic journey to integrate and streamline our organisation in order to realise synergies, reduce costs and enhance our customer value proposition. This is an effort that commenced three years ago and crystallised this year with the integration of our Health, Genetics and Advanced Nutrition salmon and shrimp offerings by species in order to drive greater synergies into those end markets.
This means we can now fully leverage our customer relationships and commercial footprint to cross-sell our offerings and develop new products and solutions. Our salmon and shrimp activities are now respectively led by Geir Olav Melingen and Patrick Waty, both strong commercial leaders, who also continue to be business area heads for Genetics and Advanced Nutrition. As a result of the change we were able to streamline the teams with immediate cost savings.
It is evident to the Board that our share price does not reflect the fundamental value of the business, its growing track record, or unique strategic positioning and attractive prospects. In an effort to address this longstanding issue, the Board decided to pursue a listing in Oslo, the leading seafood market in order to attract specialist investors and over time attain a fair valuation for our shares. An initial listing on Euronext Growth Oslo announced in November 2022 represented a first step towards this goal, to be followed by an uplisting to the Oslo Børs, subject to shareholder approval.
In 2023, we conducted a consultation with shareholders regarding an uplisting to the Oslo Børs and simultaneous delisting from AIM. However, we concluded from these discussions that it was necessary to maintain listings on both Euronext Growth Oslo and on AIM for the foreseeable future and keep an uplisting under review as part of the Group's ongoing strategy to deliver shareholder value.
During the year we made changes to the Board that increased shareholder representation, improved the gender balance, and addressed the normal Board rotation cycle.
In December we appointed Laura Lavers as Non-Executive Director. Laura is an experienced investment professional with two decades of experience and acts as shareholder representative for JNE Partners, a significant shareholder in the Company. In April, we announced the appointment of Torgeir Svae as Non- Executive Director with Atle Eide stepping down at the same time. Torgeir is an Investment Director at Kverva AS, one of the Company's main shareholders, and acts as their shareholder representative.
Following the appointments of Mrs Lavers and Mr Svae, alongside our independent directors, we have three Non-Executive Directors representing our three main shareholders who collectively hold 71% of the Company's shares.
As a step to enhance Board diversity in the normal rotation of Directors, on 30 June we appointed Marie Danielsson as Non-Executive Director and Chair of the Audit Committee succeeding Kevin Quinn who joined the Board in 2016.
In December 2023, Susan Searle, the Company's most tenured Board member, will conclude her service on the Board. The Board wishes to express its heartfelt gratitude for her exceptional contributions and dedicated work over the past decade.
Sustainability is at the core of our mission and our sustainability strategy runs across all our business and extends to our supply chain; it guides our decision-making and investment strategy. Our sustainability report including in the group's Annual Report for the year ended 30 September 2023 sets out the initiatives the progress made during the year in our three Sustainability pillars: Environment, Animal Welfare and People and Communities. We set priorities for our three pillars in alignment with a materiality assessment carried out annually which reflects key areas of impact for the business and our stakeholders. This year areas of focus included certification of our operations, sustainability of our supply chain, and enhanced climate risk assessment reporting.
Through enhanced disclosure and policies we were pleased to achieve an improvement in our MSCI ESG ratings to AA.
We have an ambitious commitment to energy transition. In 2023, we made substantial progress towards our Net Zero goals with the installation of solar panels in our facility in Thailand which represents the majority of our GHG emissions. The new solar panels will be operational in Q1 FY24.
Benchmark is driven by a group of highly talented and motivated people at all levels around the world, and I thank them all on the Board's behalf for their contribution this year. We continued to invest in making Benchmark a great place to work through an ambitious engagement programme, new learning and development resources, and regular, open communication with the management team. For a third consecutive year we obtained excellent engagement scores in our employee survey, well above the industry norm.
Our organisation is stronger than ever and, with market leading positions in our three business areas, I am confident that we will continue to build on our record of consistent delivery despite short term headwinds in some of our markets. Our focus continues to be on creating shareholder value by building a sustainably profitable, cash generative business positioned to capitalise on the opportunity to deliver healthy, nutritious, sustainable food for our future generations.
Chairman
I am pleased to report a third consecutive year of financial delivery and strategic progress at Benchmark. The change programme which we embarked on three years ago and which is ongoing has transformed Benchmark into a robust and commercial organisation with leading market positions focused on delivering growth and shareholder value.
Supported by industry megatrends and growing interest in sustainability, farming efficiency and animal welfare, Benchmark is uniquely positioned in the aquaculture industry. With a clear focus on three business areas – Genetics, Advanced Nutrition and Health we deliver specialised, mission critical solutions that address the most important challenges facing the aquaculture industry today. This creates excellent opportunities and prospects ahead for Benchmark.
We delivered good growth in revenue and Adjusted EBITDA despite challenging conditions in the global shrimp markets. This demonstrates the strength of our business and the agility of our organisation to adapt - mitigating the impact of a soft market and taking advantage of commercial opportunities to further consolidate our leading market position. We continued to build on our established track record of growth and improved profitability with revenues increasing by 7%, and Adjusted EBITDA from continuing operations excluding fair value movements from biological assets by 15%. Operating loss for the year reduced by 15% from the previous year, and total loss for the year reduced 29%. Since the end of FY20 when we completed the Group restructuring, revenues and Adjusted EBITDA from continuing operations have increased by 61% and 128%, respectively after adjusting for the divested tilapia business. In the same period, operating loss reduced by 45% and total loss for the year reduced by 32%.
Our three business areas reported good contribution and progress. Advanced Nutrition showed the strength of an excellent organisation and was able to land a good year despite weak shrimp markets which resulted in a drop in demand for our products in key markets. Genetics increased revenues by 14% driven by its core established business with record salmon egg sales from its three facilities in Iceland, Salten and Chile, and continued to invest in its growth vectors. Health reported 27% revenue growth. With leading market positions, good commercial momentum, and growth in our underlying markets we expect further organic growth in our core areas.
Innovation capability coupled with deep market insight sets us apart. During the year we strengthened our Genetics R&D team with a focus on reproductive technologies aiming to bring new breakthroughs in sterility and gene editing to the market in the coming years. In Advanced Nutrition we launched our first AI-powered artemia counting tool SnappArt, an example of how we incorporate state of the art technology into our product offering.
In addition to the growth potential across our established core business, we have three significant growth vectors which represent strategic priorities for the Group:
During the year we devoted considerable effort and resources to ensure that we have a compelling customer proposition and the right infrastructure and cost base in each of our growth vectors to deliver adequate returns.
Chile is the second largest salmon producing country in the world and a natural new market for our salmon genetics business. Barriers to entry in genetics are high and it is by leveraging our world class genetics expertise to develop a pure Chilean strain and our extensive operational capabilities that we have a competitive product in the market which is reliable, biosecure and high performing. Results from our first full production cycle demonstrate this, translating into new customer wins and a growing pipeline of orders supported by an intense commercial effort from our local and global team.
We see significant potential in shrimp genetics as a driver of growth and sustainability in shrimp production; indeed, this is an area where Benchmark has world class capabilities and expertise. We launched our first commercial shrimp genetics products in 2022 exporting breeders from our production facility in Florida to multiple markets in Asia. Based on feedback from the first commercial phase, in FY23 we decided to develop a new range of products addressing a need in the market for growth and balanced strains in addition to resistance, as well as a need for locally adapted strains tailored to variations in customer needs across countries. We undertook trials to enable product testing in local conditions and our new product development is well progressed. We also took the decision to exit our JV multiplication centre in Thailand and plan to develop alternative market routes for our shrimp genetics through partnerships with other industry players, leveraging our extensive network and established relationships. In order to leverage our leading market position and commercial network in the shrimp market through Advanced Nutrition, we combined our shrimp activities across Genetics and Advanced Nutrition under the leadership of Patrick Waty, our Head of Advanced Nutrition.
Our sea lice solution Ectosan® Vet and CleanTreat® has proven to be highly efficacious, protective of animal welfare and the environment, and represents a key growth vector for Benchmark. During the year there was increased adoption of our sea lice solution by small and large producers along the entire Norwegian coastline. Full market penetration, however, relies on the development of a new business model and configuration aligned to our customers' infrastructure. During the year we signed an agreement with a specialist wellboat equipment provider, MMC, and ship designer, SALT, to integrate CleanTreat® systems into new wellboats.
This also opens up opportunities for retro-fits or installations on platforms other than the current PSV (platform supply vessel) setup. The implementation of the new business model will allow us to streamline the organisation and reduce capital intensity. Part of these actions are reviewing different options to optimise operations and cash flow on our journey towards fully integrated customer-owned systems, including taking down the exposure to the capital intensive setup we currently hold with two PSV's.
We continue our efforts to integrate and streamline the Group - making sure we have an organisation that is as optimal as possible from an operational and commercial point of view. To this end we executed an important alignment in the year bringing together our salmon activities under the leadership of our Head of Genetics and our shrimp activities under the leadership of our Head of Advanced Nutrition. This customer-centric will enable us to increase our commercial impact with a combined offering and customer network, leveraging resources and knowledge and further strengthening our market leading position.
Our overarching aim to achieve profitability and sustainable cash generation led to the decision to exit from our tilapia breeding operation while maintaining our exposure to this species through our Genetic Services business. Having developed top performing genetics and an efficient operation and supply chain, the slow industrialisation and adoption of tilapia genetics in the industry meant that we did not see a path to adequate returns in the short and medium term. We were pleased to have exited the business through a management buyout and we continue to work with the new owners providing support for the breeding programme through our Genetics Services activities.
Benchmark's purpose driven team and culture is our most important asset. Our values underpin the way we conduct our business and create a collaborative, innovative and commercial organisation which I am very proud of. We take employee well-being and engagement seriously and create regular opportunities to facilitate dialogue. These are an important pillar in making Benchmark a 'Great Place to Work'.
We have had a good start to the year and there is good momentum in the business. We have good visibility of sales in Genetics at normalised levels following the supply shortage experienced Q1 FY23. In Advanced Nutrition we are seeing early signs of recovery in the shrimp markets which we expect will contribute positively from Q2 FY24 onwards. Our CleanTreat® units are currently operating at a good capacity utilisation and we expect this to be reflected in Q1 FY24. We expect normal seasonality with low treatment volumes in the second half. We are considering actions to optimise our operations and cashflow during the transition to an integrated customer solution. The continued integration and streamlining of the Group will enable us to further leverage the Group capabilities and drive efficiencies contributing to a positive outlook for the year ahead.
Looking into the future, we are uniquely positioned in an industry that is structurally growing. With a clear strategy addressing the main aquaculture species, we have significant opportunity to deliver growth and shareholder returns. We will continue the development of the Group and ongoing consideration of our strategy to realise the value inherent in our business for the benefit of all our stakeholders.
Trond Williksen Chief Executive Officer
We continued to develop a business structured for growth and resilience. FY23 has been a year of significant progress in which we have delivered sales growth in both Genetics and Health, our two salmon focussed business areas. Additionally, in Advanced Nutrition, we have been able to continue to make progress even despite difficult economic conditions in which the market contracted. Our continued focus on cost and cash conservation has proven key to our progress and we ended the year with healthy cash, net debt and available liquidity position. We anticipate that the shrimp markets will improve somewhat in FY24 and our shrimp focussed businesses are poised to benefit. Salmon continues to be a very solid market for the Group allowing us to continue to progress the business in line with our strategic objective to be the preferred supplier of salmon eggs in all key markets.
Overview of reported financial results During 2023, the Group's focus was on continuing to strengthen the business and deliver good commercial results and advancing its strategic priorities with the aim to be cash generative.
Advanced Nutrition continued to deliver strong results even as they faced headwinds in the shrimp markets demonstrating good resilience within the business area. Genetics had a good year with strong sales and solid results, and with Ectosan® Vet and CleanTreat® sales gaining more traction in Health this resulted in an increase in Group revenue of 7% to £169.5m in the year (2022 restated: £157.7m). This increase in sales meant that gross profit increased to £86.8m (2022 restated: £83.9m). Gross margin was slightly down at 51% (2022 restated: 53%). Using the same foreign exchange rates experienced in 2022 (constant currency⁵) revenue increased by 7%.
| 2022 | ||||
|---|---|---|---|---|
| As Reported (£m unless otherwise stated) | 2023 | restated* | % AER | % CER** |
| Revenue from continuing operations | 169.5 | 157.7 | 7% | 7% |
| Operating loss from continuing operations | (5.3) | (6.2) | 15% | 22% |
| Loss before tax from continuing operations | (12.7) | (21.4) | 41% | 44% |
| Loss for the period including discontinued operations | (21.6) | (30.5) | 29% | 31% |
| Basic loss per share (p) | (3.16) | (4.60) | 31% | – |
*2022 numbers have been restated to reflect changes to the ongoing continuing business following the disposal of the tilapia business during the year.
** Constant exchange rate (CER) is the change year on year translating current figures using last year's foreign exchange rates.
| 2022 | ||||
|---|---|---|---|---|
| Adjusted Measures (£m unless otherwise stated) | 2023 | restated* | % AER | % CER** |
| Gross profit from continuing operations | 86.8 | 83.9 | 3% | 4% |
|---|---|---|---|---|
| Gross profit % | 51% | 53% | – | – |
| Gross profit from continuing operations exc movements in fair value of biological assets |
86.9 | 82.3 | 5% | 6% |
| Gross profit % | 51% | 52% | – | – |
| Adjusted EBITDA1 from continuing operations |
35.5 | 32.6 | 9% | 11% |
| Adjusted EBITDA1 margin % | 21% | 21% | – | – |
| Adjusted EBITDA1 from continuing operations exc movements in fair value of biological assets |
35.6 | 31.0 | 15% | 16% |
| Adjusted EBITDA1 exc fair value movements margin % | 21% | 20% | – | – |
| Adjusted Operating Profit2 from continuing operations |
14.6 | 10.7 | 36% | 41% |
| Net debt3 | (65.5) | (73.7) | 11% | – |
*2022 numbers have been restated to reflect changes to the ongoing continuing business following the disposal of the tilapia business during the year.
** Constant exchange rate (CER) is the change year on year translating current figures using last year's foreign exchange rates.
1 Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and amortisation and impairment) before exceptional and acquisitionrelated items.
2 Adjusted Operating Profit is operating loss before exceptional and acquisition-related items and amortisation of intangible assets excluding development costs.
3 Net debt is cash and cash equivalents less loans, borrowings and lease obligations.
We continued to manage costs across the Group very closely. Operating costs from the continuing business increased by 2% to £45.2m (2022 restated: £44.1m) with increased costs in Genetics and Advanced Nutrition driven in the main by inflation offset by cost cuts in Health. Expensed R&D from continuing operations decreased by 9% to £6.1m (2022 restated: £6.6m).
Adjusted EBITDA from continued operations increased by 9% to £35.5m (2022 restated: £32.6m) driven by increased performance in Health which offset Genetics where we had significant investment in shrimp genetics as well as lower fair value uplift and Advanced Nutrition.
We continue to use adjusted results as our primary measures of financial performance. We believe that these adjusted measures enable a better evaluation of our underlying performance. This is how the Board monitors the progress of the Group.
We use growth at constant exchange rate metrics when considering our performance, in which currency balances are retranslated at the same exchange rates in use for the prior year to illustrate growth on a currency like-for-like basis.
In line with many of our peers in the sector, we highlight expensed R&D on the face of the income statement separate from operating expenses. Furthermore, we report earnings before interest, tax, depreciation and amortisation ("EBITDA") and EBITDA before exceptional and acquisition- related items ("Adjusted EBITDA"). The activities of the Group's equity accounted investees are closely aligned with the Group's principal activities, as these arrangements were set up to exploit opportunities from the Intellectual Property ("IP") held within the Group. As a result, to ensure that adjusted performance measures are more meaningful, the Group's share of the results of these entities is included within Adjusted EBITDA. We also report this adjusted measure after depreciation and amortisation of capitalised development costs ("Adjusted Operating Profit") as the Board considers this reflects the result after taking account of the utilisation of the recently expanded production capacity.
In addition, in line with the Salmon industry, we also report Gross profit and AEBITDA excluding fair value uplift under IAS 41. Available liquidity, being cash and undrawn facilities, is an importantmetric for management of the business as it gives a measure of the available liquid funds and is also a key financial covenant in the Group's main debt facilities.
Despite forex headwinds impacting both NOK and ISK, Genetics delivered good growth in revenue driven by sales of salmon eggs where volumes increased by 15% to 335 million eggs. Total revenues from continuing operations of £65.5m (2022 restated: £57.4m) were up 14%, 20% in constant currency.
Egg sales in our biggest market, Norway, increased by 17% during the year, with most of the demand being met by higher production volumes from our Salten facility. We also saw increased sales to almost all other territories in the year, resulting in an increase in revenue from salmon eggs of 19% to £45.6m (2022: £38.3m).
In non-product-based revenue streams, revenues from harvested fish were aided by increased salmon prices resulting in harvest income in the year of £11.1m (2022: £8.5m). Royalties earned from use of our genetic IP fell in the year, with sales down to £0.5m (2022: £0.8m). No further revenues are expected from this revenue stream as the expected unwind of contracts is now complete. Genetic Services delivered slightly lower revenues of £1.2m in the year (2022: £1.3m), but revenues from this income stream are expected to increase in future years as we build on the strength and depth of our recently expanded genetics team and our IP in the business. Revenues from other products totalled £7.4m (2022: £9.1m).
Gross profit from continuing operations reduced by 7% in 2023 to £30.6m (2022 restated: £32.8m) and gross margin fell to 47% (2022 restated: 57%). The reduction in gross margin was due to a number of factors. We experienced higher thirdparty production costs on our broodstock licence, inflation in our own costs and non-capitalisation of shrimp development costs in the year (£1.0m capitalised in 2022). Additionally, the fair value movement of bio assets fell to a reduction of £0.1m in 2023 which is a combination of a slowing in the growth of our biomass and lower eggs being incubated at the end of the year, compared to an increase of £1.6m in 2022, as the overall value of biological assets fell versus prior year.
The previously announced strategic review of our tilapia business was completed in Q4 and as a result we sold the tilapia assets in a management buy-out. Our Genetics Services team will continue to support the ongoing development of the tilapia breeding programme on an arms-length basis. The tilapia operation had revenues of £0.3m in the year (2022:£0.6m) and an AEBITDA loss of £1.3m (2022: loss of £1.4m). We also booked exceptional costs of £3.9m in the year (2022: £nil) relating to termination of the business.
Our work to refine the shrimp genetics product line is ongoing and we have lower commercial activities during the year. Prevailing conditions in the shrimp markets have also affected this area of our business. Shrimp sales in the year of £1.2m were behind last year (2022: £2.0m) and Adjusted EBITDA losses of £3.6m were £2.0m worse than prior year, £1.0m of which, as noted above, was due to capitalisation of development costs for the shrimp nucleus in 2022 before it launched commercially.
R&D spend was £0.6m lower in the year (2023: £3.7m, 2022: £4.3m) and operating costs were higher by £0.6m (2023: £11.2m, 2022: £ 10.6m) as the business grew. R&D reduced due to good cost optimisation in this area. R&D activities in this business area are focused on developing the traits of growth, disease resistance and sea lice resistance by selecting the best performing animals from each generation supported by cutting edge genetic technologies. The search for markers for new traits that can be included in the breeding programme continues.
The share of profits/losses from the equity accounted investees relates to the joint venture with Salmar Genetics AS where we recorded a share of profit of £0.03m in 2023 (2022: share of loss of £0.5m), and a share of losses of £0.2m at Benchmark Genetics Thailand (2022: share of losses of £0.1m). Post year- end, as part of consolidating the shrimp genetics business under Patrick Waty, Genetics has continued to establish its facilities in Chile and with overall AEBITDA losses of £2.9m and £0.1m invested in capex in these facilities in 2023 (2022: £3.4m and 0.6mm). These facilities have potential production capacity of 50 million eggs and is currently utilising capacity of around 30 million eggs. During the year we sold 7 million eggs.
All these factors contributed to increased AEBITDA from continuing business of £15.7m (2022 restated: £17.4m) and AEBITDA margin of 24% (2022 restated: 30%). AEBITDA from continuing business excluding fair value was the same as prior year at £15.8m (2022 restated: £15.8m) with an AEBITDA margin of 24% (2022 restated: 28%).
Throughout 2023, Advanced Nutrition delivered a resilient performance driven by continued commercial and customer focus. Advanced Nutrition had a good start to the year but at that stage we could already see weakening within the shrimp markets. This continued throughout the year but we have delivered strong results despite the market trends. Revenues in Advanced Nutrition decreased by only 2% in the year (7% at CER) as our strong commercial focus has allowed us to continue to strengthen our position and take increased market share even as the market has softened.
In 2023 and 2022, 73% of our revenues derived from shrimp, with the balance 27% of derived from the Mediterranean sea bass and sea bream sector. By product area, artemia revenue were £36.7m (2022: £37.4m) followed by diets £32.6m (2022: £35.3m). health which covers our probiotic and environmental pond management portfolio grew revenues by 13.6% to £9.2m (2022: £8.1m).
Gross profit of £43.8m (2022: £42.6m) showed an increase of 3% at AER but a reduction of 1% at CER after the effect of the foreign exchange tailwinds. However, good cost control and reducing logistics costs during the year along with lower cost of goods for our Artemia products helped support the resilience of the business. As a result we saw an increase in gross profit margin up from 53% to 56%. This increase in gross profit was offset in part by an increase in operating costs as we saw the full year effect of the investment made in the business during 2022. There continued to be strong cost control and where appropriate staff reductions throughout this year in light of difficult market conditions. Operating costs grew to £23.4m (2022: £21.5m). This led to Advanced Nutrition reporting AEBITDA of £18.4m (2022: £19.0m) and a slight decrease in AEBITDA margin from 24% to 23%.
Within this business area, an important barrier to entry is the access to GSL Artemia where we, through our relationship with the Great Salt Lakes Cooperative have access to 44% of the annual harvest of Artemia from the Great Salt Lakes.
Health reported revenue of £25.5m (2022: £20.1m) largely reflecting increased market traction for Ectosan®Vet and CleanTreat® which represented of £17.2m of revenue (2022: £14.8m) of which £4.8m relates to revenue for vessel-related costs (2022: £2.5m). Additionally, it was a good year for our other sea lice treatment, Salmosan® Vet, which showed a resurgence of demand in the year driven mainly by label changes which allow longer use in certain territories and delivered revenue of £8.3m (2022: £5.4m).
Gross profit increased by £3.8m to £12.3m, driven by the increased sales from of Ectosan®Vet and CleanTreat® combined with increased margins from Salmosan® Vet. Gross margin increased to 48% (2022: 43%), due to increased Ectosan®Vet and CleanTreat® sales.
During the year, the focus of this business area has been to drive demand for Ectosan®Vet and CleanTreat® in Norway and also to lay the ground work for moving the Cleantreat® treatments away from Benchmark leased and controlled vessels, onto customer owned platforms. This will reduce the capital intensive nature of the solution and ultimately reduce costs for the customer, making it a more attractive solution to use for the treatment of sea lice. To date capacity utilisation on the Cleantreat® vessels varied with treatment seasonality which translated into utilisation of c.50% in each vessel during FY23. We are reviewing different options to manage capacity and optimise operations and cash flow as we transition towards fully integrated customer owned systems on wellboats. This may include reducing the exposure to the capital intensive setup we currently hold with two PSV's. With cash and cost control being a very key focus for this business area, operating costs decreased to £7.3m (2022: £8.1m) and research and development fell to £0.3m (2022: £0.4m). Adjusted EBITDA for the business area was £4.8m (2022: £0.1m). AEBITDA margin was 19% for 2023 (2022: 1%).
Within Health and Genetics, given the commonality of customers we adopted a single sales and marketing team approach which has been in place during the financial year. To further drive these efforts, Health and Genetics were brought under common operational leadership during the year under Geir Olav Melingen. We will continue to report these as separate segments to aid in transparency of results.
As noted earlier, cost control remains of significant importance in Benchmark and in the current inflationary environment becomes even more so. During the year, we saw higher cost inflation in a number of areas, the most significant of which related to salaries. Within Health we were able to mitigate this by reducing the overall number of headcount and limiting discretionary spend. Within Genetics and Advanced Nutrition, we have, within the constraints of existing contracts, tried to increase prices and also limit discretionary spend to mitigate. Within Advanced Nutrition, a number of roles were also reorganised to make the operation leaner to best fit the current market conditions.
Items that are material because of their nature whose significance is sufficient to warrant separate disclosure and identification within the consolidated financial statements are referred to as exceptional items. The separate reporting of exceptional items helps to provide an understanding of the Group's underlying performance.
| 2023 | 2022 | |
|---|---|---|
| £mil | £mil | |
| Aborted acquisition related items | 0.6 | – |
| Exceptional restructuring costs | 0.9 | 1.2 |
| Costs associated with the Oslo listing | 2.6 | – |
| Cost in relation to disposals | (0.2) | (1.2) |
| Total exceptional items | 3.9 | (nil) |
The above table excludes £3.9m of exceptionals included within discontinued operations as mentioned earlier.
Exceptional expenses in 2023 were mainly driven by legal and professional costs in relation to the dual listing on the Oslo exchange of and consideration of uplisting to the Oslo Børs of £2.6m. Within Health and Advanced Nutrition some restructuring occurred during the year, in Health to move towards the integration of the operational leadership and within Advanced Nutrition to adapt to the changes in the markets. This resulted in costs of £0.9m (2022: £1.2m). The costs were offset by a credit of £0.2m (2022: £1.2m) relating to additional contingent consideration received in the period following the disposal of Improve International on 23 June 2020, actually cash received was £1.25m related to this divestment.
Depreciation and impairment of tangible assets including discontinued operations and right of use assets was £18.7m (2022 restated: £19.9m). In total, depreciation and impairment charges on right of use assets under IFRS 16 was £10.3m (2022 restated: £11.3m). The charge within discontinued operations included above was £0.3m (2022: £0.2m). Amortisation and impairment of intangible assets totalled £18.5m (2022: £19.2m). This includes an impairment charge of £0.5m related to some intellectual property within Health which is deemed no longer to be of value. We expect the amortisation charge to start reducing from FY25 as some of the Advanced Nutrition (INVE) assets will be fully amortised then.
| Expensed Total expensed and capitalised |
||||||||
|---|---|---|---|---|---|---|---|---|
| 2023 | 2023 | |||||||
| £m | Continuing | As % of | 2022 | As % of | Continuing | As % of | 2022 | As % of |
| business | sales | restated | sales | business | sales | restated | sales | |
| Expensed R&D by business area | ||||||||
| Genetics | 3.7 | 6% | 4.3 | 7% | 3.7 | 6% | 5.2 | 9% |
| Advanced Nutrition | 2.1 | 3% | 2.0 | 2% | 2.1 | 3% | 2.1 | 3% |
| Health | 0.3 | 1% | 0.4 | 2% | 0.9 | 4% | 1.0 | 5% |
| Total research and development | 6.1 | 4% | 6.7 | 4% | 6.7 | 4% | 8.3 | 5% |
Expensed R&D activities decreased in the year by £0.5m with Genetics having good cost optimisation in this area while continuing to focus on improvements in the breeding nucleus. Health spending remained low due to their significantly reduced R&D programmes. Genetics' research is focused around continually developing new disease and parasitic resistant traits as well as growth traits which we can breed into our products. Advanced Nutrition's focus is on expanding our product portfolio and driving growth through product improvements.
| As % of | 2022 | As % of | ||
|---|---|---|---|---|
| £m | 2023 | sales | restated | sales |
| Operating Expenses for continuing business by Business Area | ||||
| Genetics | 11.2 | 17% | 10.6 | 18% |
| Advanced Nutrition | 23.4 | 30% | 21.5 | 27% |
| Health | 7.3 | 29% | 8.1 | 40% |
| Corporate (net) | 3.3 | 3.9 | ||
| Total operating expenses | 45.2 | 27% | 44.1 | 28% |
Other operating costs within the continuing business increased from £44.1m in 2022 (restated) to £45.2m in 2023. The modest increase in costs reflects the impact of cost inflation being mitigated by good cost control and limiting discretionary spend.
During the year we initiated a strategic review of our tilapia operations with a view to understanding the timeline to cash generation within the area of our Genetics business. As a consequence of this review we divested the business via a management buy-out in the fourth quarter of the financial year.
| 2022 | ||
|---|---|---|
| £m | 2023 | restated |
| Interest Income | (0.6) | (0.3) |
| Foreign Exchange gains | (0.3) | (2.8) |
| Interest on bond and bank debt | 8.4 | 6.2 |
| Amortisation of deferred financing fees | 0.5 | 1.9 |
| Penalty for early settlement of the bond | – | 1.6 |
| Movements in hedging instruments | (2.2) | 7.0 |
| Finance lease interest | 1.6 | 1.6 |
| Total net finance expenses | 7.4 | 15.2 |
The Group incurred net finance costs of £7.4m during the year (2022 restated: £15.2m). Included within this was interest charged on the Group's interest-bearing debt facilities of £8.4m (2022: £6.2m), the higher interest cost was due to higher utilisation of the RCF facility during the year and also higher interest coupon on the bond. In addition, a further £0.5m was charged on amortisation of the deferred finance costs (2022: £1.9m). Net foreign exchange gains of £0.3m (2022 restated: net gain of £2.8m) arose due to the movement in exchange rates on intercompany loans and external debt. Movements on the hedging instruments associated with the Group's NOK bond debt resulted in gains of £2.2m (2022: loss of £7.0m).
The loss before tax from continuing operations for the year at £12.7m is lower than the prior year (2022 restated: loss of £21.4m). This was a result of the positive trading result offset by higher exceptional items and lower finance costs due to changes in fair value of in-effective portion of cash flow hedges slightly offset by unfavourable foreign exchange movements.
There was a tax charge on the loss for the year of £3.4m (2022: £7.3m), mainly due to overseas tax charges in Genetics and Advanced Nutrition in territories where no loss relief is available, partially offset by deferred tax credits on intangible assets mainly arising on consolidation from acquisitions.
In addition to the loss for the year of £21.6m, there was a significant movement of £23.0m in OCI resulting from movements in the foreign exchange and hedging reserves. The forex loss of £23.5m was driven by USD and NOK impacting the retranslation of foreign currency denominated subsidiary balance sheets into GBP offset by amounts designated as net investment hedges, together with long term internal loans not expected to be repaid in the foreseeable future which are treated like equity with the movements going directly to reserves. These were offset by £0.5m credit into the hedge reserve from hedge accounting on cashflow hedges.
During 2023, we obtained approval via the AGM to cancel part of the share premium account and transfer it to retained earnings. This amounted to £394.2m. This has allowed the business to increase its distributable reserves and serves as a step towards the goal of being a cash generative group, able to issue dividends in line with its dividend policy.
The loss for the year from the continuing business was £16.1m (2022 restated: loss of £28.7m). The total loss from continuing activities and discontinued operations was £21.6m (2022: £30.5m).
Basic loss and diluted loss per share were both 3.16p (2022: loss per share 4.60p). The movement year on year is due to the movement in the result as well as the increase in the weighted average number of shares in issue of 33.7m.
No dividends have been paid or proposed in either 2023 or 2022 and the Board is not recommending a final dividend in respect of the year ended 30 September 2023.
A feature of the Group's net assets is its investment in biological assets, which under IAS 41 are stated at fair value. At 30 September 2023, the carrying value of biological assets was £46.0m (2022: £46.7m). This decrease is due principally to the reduction in eggs available for sale in FY24 compared to FY23, as demand for our eggs was higher at the start of FY23 while there were supply issues in the market which did not affect Benchmark. This has normalised during the year. The fair value movement on biological assets included in cost of sales for the year was a reduction of £0.1m (2022: uplift of £1.6m).
Additions to intangibles were £0.8m (2022: £1.9m) with the main area of investment being capitalised development costs which in the year decreased by £1.1m to £0.6m (2022: £1.7m). R&D costs related to products that are close to commercial launch have to be capitalised when they meet the requirements set out under IAS 38. In this financial year, the main development project capitalised was Salmosan Vet (£0.6m).
During 2023, to manage cash, we curtailed the investment incurred and focussed on purely business critical areas. The Group incurred tangible fixed asset additions of £6.0m (2022: £10.8m) broken down as follows:
Within Health, there was an increase in the provision to demobilise the Cleantreat® units from the current vessels of £0.4m and additional equipment for the existing Cleantreat® units of £0.3m. Capex associated with our Genetics business was £3.4m where we finished the building of new tanks at Salten to support ramping up to the 150 million egg capacity at that facility (£1.4m) and we continue to invest in our production footprint in Iceland and Salten. 2023 saw minimal investment in our growth initiatives in Chile and shrimp as we believe they have been sufficiently invested. In Advanced Nutrition we continued to invest in the two manufacturing facilities to support growth and operational efficiency.
| 2023 £m |
2022 £m |
|
|---|---|---|
| Movement in net debt |
||
| Net debt at 30 September 2022/2021 |
(73.7) | (80.9) |
| Cash generated from operations excluding working capital and taxes paid | 29.6 | 30.3 |
| Investment in working capital |
(1.1) | (12.0) |
| Capital expenditure | (6.8) | (12.7) |
| Other disposal activities |
0.2 | (0.2) |
| Foreign exchange on cash and debt |
4.3 | 10.5 |
| Interest and tax |
(17.1) | (17.0) |
| Proceedsfrom previous year disposals of subsidiaries |
1.3 | 1.5 |
| Acquisition of subsidiaries net of cash/debt acquired |
(0.2) | – |
| Investment in associates |
(0.6) | (0.4) |
| Acquisition of non controlling interest |
(8.0) | – |
| Additionsto/modifications of leases(IFRS 16) |
(3.7) | (11.5) |
| Shares issued |
10.9 | 20.2 |
| Other non-cash movements | (0.6) | (1.5) |
| Net debt at 30 September 2023/2022 |
(65.5) | (73.7) |
With improved trading in the business, we saw strong cash generated from operations of £29.6m (2022: £30.3m). During 2023 with significant focus on cash conservation, we restricted the investment in working capital to £1.1m versus an outflow last year £12.0m. Interest and taxes were in line with last year. Capital expenditure, both intangible and tangible, showed a significant decrease of £5.9m to £6.8m (2022: £12.7m) as we continue to moderate our capex.
Working capital has reduced slightly in the period driven by a number of factors. We can see the impact of foreign exchange on the balance sheet as noted above in the other comprehensive income section and this impacted the working capital balances at 30 September 2023, but our investment in working capital was more moderate this year as can be seen in the cash flow.
We noted earlier the decrease in biological assets within the genetics areas. Other Inventories fell in Advanced Nutrition as we had less GSL Artemia in inventory than previous years.
In Health, we had transferred the CleanTreat® equipment into inventory in 2022 but we had lower levels of inventory of Salmosan® Vet than 2022.
Trade debtors and creditors, of course, increased as a result of increased sales but trade debtors decreased as a percentage of sales from 20% to 16% in the year. Trade payables were 20% higher than last year as expected from higher level of costs both from activity levels and from cost inflation.
A significant amount of cash is tied up with the working capital of the group and focus will continue to be on releasing that investment in the years to come.
The Group has a senior unsecured green bond issue of NOK 750 million, with an expected maturity date of 27 September 2025. The bond has a coupon of three months NIBOR* + 6.5% p.a. with quarterly interest payments. The Group also had a USD 15m revolving credit facility ("RCF") which was due to mature in December 2022 and had £4m drawn at 30 September 2022. During the year, this RCF was refinanced by a new £20m RCF on 21 November 2022 with a June 2025 maturity. The interest rate on the facility is between 2.5% and 3.25% above compound interest rate depending on leverage. At 30 September 2023, there was £7.75m drawn on this facility (2022: £4.0m).
There are other borrowing facilities held within Benchmark Genetics Salten AS which were originally put in place to fund the building of the Salten salmon eggs facility. On 1 November 2022 the term loan facility outstanding balance and the overdraft facility provided by Nordea were refinanced into one facility totalling NOK179.5m with a maturity date of January 2028. The margin on the new facility is 2.5%. In addition, a working capital facility of NOK 20.0m (renewal annually in March) is in place for use solely by Benchmark Genetics Salten AS. This facility is undrawn (2022: undrawn). Two additional ten-year term loans of NOK 25,000,000 and NOK 30,000,000 respectively provided by Innovasjon Norge in 2018. These loans currently have a flat interest rate of 5.95% per annum.
| £m | 2023 | 2022 |
|---|---|---|
| Cash | 36.5 | 36.4 |
| NOK 750m bond | (57.6) | (62.0) |
| Other borrowings | (24.5) | (21.8) |
| Lease liabilities | (19.9) | (26.3) |
| Net debt | (65.5) | (73.7) |
The RCF combined with the year-end cash balance of £36.5m (2022: £36.4m) means the Group had total liquidity of £48.8m (2022: £45.8m). This, while utilising tight cost and cash control, is expected by the Directors to provide the Group with sufficient liquidity to fund the investment and working capital required to crystalise the growth opportunities which are part of the strategic priorities of the Group and provide adequate headroom.
In December 2022, £10.8m net proceeds were raised through a placing to provide the Company with sufficient free float to establish a listing on Oslo Euronext Growth. The listing was completed on 15 December 2022 and we have remained dual listed since that time. During 2023, the Board considered an uplisting to Oslo Børs but ultimately through shareholder consultation, the decision was made to remain dual listed on Euronext Growth and AIM. The proceeds of this equity raise facilitated us in having sufficient available cash to purchase the minority interest in our Icelandic operation.
Banking covenants for the NOK bond and RCF exist in relation to liquidity and an 'equity ratio'. Liquidity, defined as 'freely available and unrestricted cash and cash equivalents, including any undrawn amounts under the RCF', must always exceed the minimum liquidity value, set at £10m. Available liquidity at 30 September 2023 is £48.8m (2022: £45.8m). The equity ratio, defined as 'the ratio of Book Equity to Total Assets' must always exceed 40%. The equity ratio at 30 September 2023 was 60% (2022: 61%). In addition, an equity to asset ratio covenant exists for the Benchmark Genetics Salten AS debt with a target threshold of 40%, this equity to asset ratio was 60.0% at 30 September 2023 (2022: 51.3%).
In December 2014 Benchmark acquired an 89.48% interest in Stofnfiskur, subsequently rebranding it Benchmark Genetics Iceland. Since the acquisition, the business has grown substantially, benefitting from Benchmark's leading market position, investment and knowledge transfer within the Group. In February 2023, we acquired the remaining 10.52% minority interest in Benchmark Genetics Iceland for a consideration of €9m. This acquisition is strategically important as Benchmark Genetics Iceland is core to the Company's ability to supply highly specialist, biosecure salmon eggs year-round to salmon producers in c.25 countries around the world. Benchmark Genetics Iceland represents 50% of the Group's salmon egg capacity.
As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m), including cash of £36.5m (2022: £36.4m) as set out in the Consolidated Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m). As at 30 September 2023 the Company had net assets of £363.2m (2022: £346.6), including cash of £0.3m (2022: £3.2m) as set out on the Company Balance Sheet. The Company made a loss for the year of £4.2m (2022: £16.5m).
As noted in the Strategic Report, the business has performed steadily during the year, showing resilience to some tough market conditions towards the end of the year. The Directors have reviewed forecasts and cash flow projections for a period of at least 12 months including downside sensitivity assumptions in relation to trading performance across the Group to assess the impact on the Group's trading and cash flow forecasts and on the forecast compliance with the covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but plausible scenarios on the Group's trading and cash flow forecasts, firstly in relation to continued roll out of the Ectosan® Vet and CleanTreat® offering. Sensitivities considered included modelling slower ramp up of the commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out of the revised operating model for the service, together with reductions in expected biomass treated and reduction in short-term treatment capacity. Key downside sensitivities modelled in other areas included assumptions on slower commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and removal of an additional financing opportunity within Genetics, along with sensitivities on sales growth in revenues and pressure on pricing on CIS artemia in Advanced Nutrition. Mitigating measures within the control of management have been identified should they be required in response to these sensitivities, including reductions in areas of discretionary spend, tight control over new hires, deferral of capital projects and temporary hold on R&D for non-imminent products.
The refinancing exercise which commenced in FY22 was completed at the start of FY23, so that adequate finance facilities are in place, and with financial instruments in place to fix interest rates and opportunities available to mitigate globally high inflation rates, the Group continues to show resilience against current global economic pressures. The Directors are therefore confident that even under all of the above sensitivity analysis, the Group has sufficient liquidity and resources throughout the period under review whilst still maintaining adequate headroom against the borrowing covenants. They therefore remain confident that the Group has adequate resources to continue to meet its liabilities as and when they fall due within the period of 12 months from the date of approval of these financial statements. Based on their assessment, the Directors believe it remains appropriate to prepare the financial statements on a going concern basis.
| 2023 £000 |
2022 Restated* £000 |
||
|---|---|---|---|
| Revenue | 169,476 | 157,707 | |
| Cost ofsales | (82,726) | (73,777) | |
| Gross profit | 86,750 | 83,930 | |
| Research and development costs | (6,069) | (6,634) | |
| Other operating costs | (45,157) | (44,095) | |
| Share of (loss)/profit of equity-accounted investees, net of tax | (32) | (595) | |
| Adjusted EBITDA² | 35,492 | 32,606 | |
| Exceptional – restructuring/acquisition and disposal related items | 4 | (3,904) | 16 |
| EBITDA¹ | 31,588 | 32,622 | |
| Depreciation and impairment | (18,409) | (19,692) | |
| Amortisation and impairment | (18,495) | (19,161) | |
| Operating loss | (5,316) | (6,231) | |
| Finance cost | 3 | (15,048) | (19,893) |
| Finance income | 3 | 7,670 | 4,741 |
| Loss before taxation | (12,694) | (21,383) | |
| Tax on loss | (3,365) | (7,268) | |
| Lossfrom continuing operations | (16,059) | (28,651) | |
| Discontinued operations | |||
| Lossfrom discontinued operations, net of tax | 5 | (5,505) | (1,800) |
| (21,564) | (30,451) | ||
| Lossfor the year attributable to: | |||
| – Owners of the parent | (23,146) | (32,087) | |
| – Non-controlling interest | 1,582 | 1,636 | |
| (21,564) | (30,451) | ||
| Earnings pershare | |||
| Basic loss per share (pence) | 6 | (3.16) | (4.60) |
| Diluted loss pershare (pence) | 6 | (3.16) | (4.60) |
| Earnings pershare - continuing operations | |||
| Basic loss per share (pence) | 6 | (2.41) | (4.34) |
| Diluted loss pershare (pence) | 6 | (2.41) | (4.34) |
| £000 | £000 | ||
| Adjusted EBITDA from continuing operations | 35,492 | 32,606 | |
| Adjusted EBITDA from discontinued operations | (1,254) | (1,425) |
Total Adjusted EBITDA 34,238 31,181
EBITDA – earnings before interest, tax, depreciation, amortisation and impairment.
Adjusted EBITDA – EBITDA before exceptional and acquisition-related items.
* 2022 numbers have been restated to reflect certain operations of the Group that have been classified as discontinued operations during the year in line with IFRS 5
for the year ended 30 September 2023
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Lossfor the year | (21,564) | (30,451) |
| Other comprehensive income | ||
| Itemsthat are or may be reclassified subsequently to profit or loss | ||
| Foreign exchange translation differences | (23,475) | 47,606 |
| Cash flow hedges – changes in fair value | (2,123) | 2,627 |
| Cash flow hedges – reclassified to profit or loss | 2,623 | 2,546 |
| Total comprehensive income for the period | (44,539) | 22,328 |
| Total comprehensive income for the period attributable to: | ||
| – Owners of the parent | (45,404) | 20,326 |
| – Non-controlling interest | 865 | 2,002 |
| (44,539) | 22,328 | |
| Total comprehensive income for the period attributable to owners of the parent: | ||
| – Continuing operations | (39,777) | 21,509 |
| – Discontinued operations* | (5,627) | (1,183) |
| (45,404) | 20,326 |
* Total comprehensive income for the period relating to discontinued operations for FY23 includes the loss of £5,505,000 (2022: £1,800,000) and foreign exchange loss of £122,000 (2022: gain of £617,000).
as at 30 September 2023
| Notes | 2023 £000 |
2022 £000 |
|---|---|---|
| Assets | ||
| Property, plant and equipment 7 |
73,411 | 81,900 |
| Right-of-use assets 8 |
19,804 | 27,034 |
| Intangible assets 9 |
206,077 | 245,264 |
| Equity-accounted investees | 3,558 | 3,113 |
| Other investments | 14 | 15 |
| Biological and agricultural assets 11 |
18,406 | 20,878 |
| Non-current assets | 321,270 | 378,204 |
| Inventories | 25,269 | 29,813 |
| Biological and agricultural assets 11 |
27,586 | 25,780 |
| Trade and other receivables 10 |
59,795 | 56,377 |
| Cash and cash equivalents | 36,525 | 36,399 |
| 149,175 | 148,369 | |
| Assets held forsale | 850 | – |
| Current assets | 150,025 | 148,369 |
| Total assets | 471,295 | 526,573 |
| Liabilities | ||
| Trade and other payables 13 |
(47,329) | (44,324) |
| Loans and borrowings 14 |
(20,045) | (17,091) |
| Corporation tax liability | (6,422) | (10,211) |
| Provisions | (1,280) | (1,631) |
| Current liabilities | (75,076) | (73,257) |
| Loans and borrowings 14 |
(81,954) | (93,045) |
| Other payables 13 |
(6,842) | (8,996) |
| Deferred tax | (24,106) | (27,990) |
| Provisions | (700) | – |
| Non-current liabilities | (113,602) | (130,031) |
| Total liabilities | (188,678) | (203,288) |
| Net assets | 282,617 | 323,285 |
| Issued capital and reserves attributable to owners of the parent | ||
| Share capital | 739 | 704 |
| Additional paid-in capital | 37,428 | 420,824 |
| Capital redemption reserve | 5 | 5 |
| Retained earnings | 183,489 | (185,136) |
| Hedging reserve | (203) | (703) |
| Foreign exchange reserve | 54,947 | 77,705 |
| Equity attributable to owners of the parent | 276,405 | 313,399 |
| Non-controlling interest | 6,212 | 9,886 |
| Total equity and reserves | 282,617 | 323,285 |
The financialstatements were approved and authorised for issue by the Board of Directors on 29 November 2023 and were signed on its behalf by:
Septima Maguire Chief Financial Officer
Company number: 04115910
for the year ended 30 September 2023
| Share capital £000 |
Additional paid-in share capital £000 |
Other reserves £000 |
Hedging reserve £000 |
Retained earnings £000 |
Total attributable to equity holders of parent £000 |
Non controlling interest £000 |
Total equity £000 |
|
|---|---|---|---|---|---|---|---|---|
| As at 1 October 2021 | 670 | 400,682 | 30,470 | (5,876) | (154,231) | 271,715 | 7,884 | 279,599 |
| Comprehensive income for the year | ||||||||
| (Loss)/profit for the year | – | – | – | – | (32,087) | (32,087) | 1,636 | (30,451) |
| Other comprehensive income | – | – | 47,240 | 5,173 | – | 52,413 | 366 | 52,779 |
| Total comprehensive income for the year | – | – | 47,240 | 5,173 | (32,087) | 20,326 | 2,002 | 22,328 |
| Contributions by and distributions to owners |
||||||||
| Share issue | 34 | 20,704 | – | – | – | 20,738 | – | 20,738 |
| Share issue costsrecognised through equity |
– | (562) | – | – | – | (562) | – | (562) |
| Share-based payment | – | – | – | – | 1,182 | 1,182 | – | 1,182 |
| Total contributions by and distributions to owners | 34 | 20,142 | – | – | 1,182 | 21,358 | – | 21,358 |
| Changesin ownership | ||||||||
| Acquisition of NCI | – | – | – | – | – | – | – | – |
| Total changes in ownership interests | – | – | – | – | – | – | – | – |
| Total transactions with owners of the Company |
34 | 20,142 | – | – | 1,182 | 21,358 | – | 21,358 |
| As at 30 September 2022 | 704 | 420,824 | 77,710 | (703) | (185,136) | 313,399 | 9,886 | 323,285 |
| Comprehensive income for the year | ||||||||
| (Loss)/profit for the period | – | – | – | – | (23,146) | (23,146) | 1,582 | (21,564) |
| Other comprehensive income | – | – | (22,758) | 500 | – | (22,258) | (717) | (22,975) |
| Total comprehensive income for the year | – | – | (22,758) | 500 | (23,146) | (45,404) | 865 | (44,539) |
| Contributions by and distributions to owners | ||||||||
| Share issue | 35 | 12,985 | – | – | – | 13,020 | – | 13,020 |
| Share issue costs recognised through equity | – | (2,146) | – | – | – | (2,146) | – | (2,146) |
| Cancellation of part of share premium account | – | (394,235) | – | – | 394,235 | – | – | – |
| Share-based payment | – | – | – | – | 1,006 | 1,006 | – | 1,006 |
| Total contributions by and distributions to owners | 35 | (383,396) | – | – | 395,241 | 11,880 | – | 11,880 |
| Changesin ownership | ||||||||
| Acquisition of NCI | – | – | – | – | (3,470) | (3,470) | (4,359) | (8,009) |
| Total changes in ownership interests | – | – | – | – | (3,470) | (3,470) | (4,359) | (8,009) |
| Total transactions with owners of the Company |
35 | (383,396) | – | – | 391,771 | 8,410 | (4,539) | (8,009) |
| As at 30 September 2023 | 739 | 37,428 | 54,952 | (203) | 183,489 | 276,405 | 6,212 | 282,617 |
for the year ended 30 September 202 3
| 2023 | 2022 | |
|---|---|---|
| £000 Notes |
£000 | |
| Cash flowsfrom operating activities | ||
| Lossfor the year | (21,564) | (30,451) |
| Adjustments for: | ||
| Depreciation and impairment of property, plant and equipment Depreciation and impairment of right -of -use assets |
8,453 10,260 |
8,602 11,293 |
| Other adjustments for non -cash items |
– | (276) |
| Amortisation and impairment of intangible fixed assets | 18,495 | 19,161 |
| Profit on sale of property, plant and equipment | (121) | (43) |
| Loss on sale of discontinued operation | 3,774 | – |
| Finance income | (2,802) | (319) |
| Finance costs | 10,535 | 18,437 |
| Increase in fair value of contingent consideration receivable | – | (1,203) |
| Share of loss of equity -accounted investees, net of tax |
32 | 595 |
| Foreign exchange gains | (1,814) | (3,985) |
| Share -based payment expense |
1,00 5 |
1,182 |
| Tax expense | 3,365 | 7,274 |
| Increase in trade and other receivables | (6,570) | (8,511) |
| Decrease/(increase) in inventories | 2,87 7 |
(5,406) |
| Increase in biological and agricultural assets | (1,659) | (6,099) |
| Increase in trade and other payables | 3,909 | 6,948 |
| Increase in provisions | 386 | 1,058 |
| 28,561 | 18,257 | |
| Income taxes paid | (8,556) | (7,447) |
| Net cash flows generated from operating activities | 20,005 | 10,810 |
| Investing activities | ||
| Acquisition ofsubsidiaries | (48) | – |
| Purchase of investmentsin associates | (558) | (378) |
| Receiptsfrom disposal ofsubsidiaries | 1,250 | 1,544 |
| Purchases of property, plant and equipment | (5,953) | (10,808) |
| Purchase of intangibles | (196) | (205) |
| Capitalised research and development costs | (632) | (1,708) |
| Proceedsfrom sale of fixed assets | 227 | 220 |
| Cash receiptsfrom swap contracts | 11 | – |
| Interest received | 627 | 119 |
| Net cash flows used in investing activities | (5,272) | (11,216) |
| Financing activities | ||
| Proceeds ofshare issues | 13,020 | 20,737 |
| Share -issue costs recognised through equity |
(2,146) | (562) |
| Acquisition of minority interests in subsidiaries | (8,009) | – |
| Proceedsfrom bank or other borrowings | 21,847 | 67,939 |
| Repayment of bank or other borrowings | (18,470) | (74,874) |
| Interest and finance charges paid | (9,131) | (9,629) |
| Repayments of lease liabilities | (9,438) | (10,533) |
| Net cash used in financing activities | (12,327) | (6,922) |
| Net increase/(decrease) in cash and cash equivalents | 2,406 | (7,328) |
| Cash and cash equivalents at beginning of year | 36,399 | 39,460 |
| Effect of movements in exchange rate | (2,280) | 4,267 |
| Cash and cash equivalents at end of year | 36,525 | 36,399 |
These audited results have been prepared on the basis of the accounting policies which are to be set out in Benchmark Holdings Plc's annual report and financial statements for the year ended 30 September 2023. Those policies have been consistently applied to all the years presented unless otherwise stated.
These Group and parent company financial statements were prepared and approved by the Directors in accordance with (i) UK-adopted International Accounting Standards and (ii) IFRS adopted pursuant to Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted IFRS"). While the financial information included in this preliminary statement has been prepared on the basis of the requirements of IFRSs in issue, this statement does not itself contain sufficient information to comply with IFRS.
The financial information set out above does not constitute the company's statutory accounts for the years ended 30 September 2023 or 2022 but is derived from those accounts. Statutory accounts for 2022 have been delivered to the registrar of companies, and those for 2023 will be delivered in due course. The auditor has reported on those accounts. The auditor's reports for 2023 and for 2002 were both (i) unqualified and (ii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006.
The financial statements are prepared on the historical cost basis except that the following assets and liabilities are stated at their fair value: certain financial assets and financial liabilities (including contingent consideration receivable and derivatives) and biological assets measured at fair value. Non-current assets and disposal groups held for sale are stated at the lower of previous carrying amount and fair value less costs to sell.
As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m), including cash of £36.5m (2022: £36.4m) as set out in the Consolidated Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m).
As noted in the Strategic Report, the business has performed steadily during the year, showing resilience to some tough market conditions towards the end of the year. The Directors have reviewed forecasts and cash flow projections for a period of at least 12 months including downside sensitivity assumptions in relation to trading performance across the Group to assess the impact on the Group's trading and cash flow forecasts and on the forecast compliance with the covenants included within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but plausible scenarios on the Group's trading and cash flow forecasts, firstly in relation to continued roll out of the Ectosan®Vet and CleanTreat offering. Sensitivities considered included modelling slower ramp up of the commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out of the revised operating model for the service, together with reductions in expected biomass treated and reduction in short-term treatment capacity. Key downside sensitivities modelled in other areas included assumptions on slower commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and removal of an additional financing opportunity within Genetics, along with sensitivities on sales growth in revenues and pressure on pricing on CIS artemia in Advanced Nutrition. Mitigating measures within the control of management have been identified should they be required in response to these sensitivities, including reductions in areas of discretionary spend, tight control over new hires, deferral of capital projects and temporary hold on R&D for non-imminent products.
The refinancing exercise which commenced in FY22 was completed at the start of FY23, so that adequate finance facilities are in place, and with financial instruments in place to fix interest rates and opportunities available to mitigate globally high inflation rates, the Group continues to show resilience against current global economic pressures. The Directors are therefore confident that even under all of the above sensitivity analysis, the Group has sufficient liquidity and resources throughout the period under review whilst still maintaining adequate headroom against the borrowing covenants. They therefore remain confident that the Group has adequate resources to continue to meet its liabilities as and when they fall due within the period of 12 months from the date of approval of these financial statements. Based on their assessment, the Directors believe it remains appropriate to prepare the financial statements on a going concern basis.
Operating segments are reported in a manner consistent with the reports made to the chief operating decision maker. It is considered that the role of chief operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into reportable segments based on the following business areas:
In order to reconcile the segmental analysis to the Consolidated Income Statement, corporate and inter-segment sales are also shown. Corporate sales represent revenues earned from recharging certain central costs to the operating business areas, together with unallocated central costs.
Inter-segment sales are priced along the same lines as sales to external customers, with an appropriate discount being applied to encourage use of Group resources at a rate acceptable to local tax authorities. This policy was applied consistently throughout the current and prior period.
| Year ended 30 September 2023 | Genetics £000 |
Advanced Nutrition £000 |
Health £000 |
Corporate £000 |
Inter segment sales £000 |
Total £000 |
|---|---|---|---|---|---|---|
| Revenue | 65,791 | 78,503 | 25,514 | 5,747 | (5,811) | 169,744 |
| Cost ofsales | (35,876) | (34,704) | (13,173) | - | 54 | (83,699) |
| Gross profit / (loss) | 29,915 | 43,799 | 12,341 | 5,747 | (5,757) | 86,045 |
| Research and development costs | (3,778) | (2,071) | (279) | - | - | (6,128) |
| Operating costs | (11,696) | (23,354) | (7,290) | (9,064) | 5,757 | (45,647) |
| Share of profit of equity-accounted investees, net of tax | (32) | - | - | - | - | (32) |
| Adjusted EBITDA | 14,409 | 18,374 | 4,772 | (3,317) | - | 34,238 |
| Exceptional – restructuring/acquisition and disposal related items |
(3,913) | (920) | (509) | (2,475) | - | (7,817) |
| EBITDA | 10,496 | 17,454 | 4,263 | (5,792) | - | 26,421 |
| Depreciation and impairment | (4,703) | (2,437) | (11,559) | (14) | - | (18,713) |
| Amortisation and impairment | (1,894) | (14,269) | (2,329) | (3) | - | (18,495) |
| Operating profit / (loss) | 3,899 | 748 | (9,625) | (5,809) | - | (10,787) |
| Finance cost | (15,082) | |||||
| Finance income | 7,670 | |||||
| Loss before tax | (18,199) |
| Year ended 30 September 2022 | Genetics £000 |
Advanced Nutrition £000 |
Health £000 |
Corporate £000 |
Inter segment sales £000 |
Total £000 |
|---|---|---|---|---|---|---|
| Revenue | 58,008 | 80,286 | 20,135 | 5,120 | (5,272) | 158,277 |
| Cost ofsales | (25,971) | (37,733) | (11,544) | 4 | 95 | (75,149) |
| Gross profit / (loss) | 32,037 | 42,553 | 8,591 | 5,124 | (5,177) | 83,128 |
| Research and development costs | (4,329) | (1,990) | (372) | – | – | (6,691) |
| Operating costs | (11,133) | (21,546) | (8,111) | (9,048) | 5,177 | (44,661) |
| Share of profit of equity-accounted investees, net of tax | (595) | – | – | – | – | (595) |
| Adjusted EBITDA | 15,980 | 19,017 | 108 | (3,924) | – | 31,181 |
| Exceptional – restructuring/acquisition and disposal related | ||||||
| items | – | (220) | 18 | 218 | – | 16 |
| EBITDA | 15,980 | 18,797 | 126 | (3,706) | – | 31,197 |
| Depreciation and impairment | (5,322) | (2,236) | (12,251) | (88) | – | (19,897) |
| Amortisation and impairment | (1,695) | (15,000) | (2,463) | (3) | – | (19,161) |
| Operating profit / (loss) | 8,963 | 1,561 | (14,588) | (3,797) | – | (7,861) |
| Finance cost | (20,057) | |||||
| Finance income | 4,741 | |||||
| Loss before tax | (23,177) |
Non-current assets by location of assets
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Belgium | 144,344 | 173,136 |
| Norway | 74,541 | 83,752 |
| UK | 29,690 | 42,373 |
| Iceland | 37,631 | 39,448 |
| Rest of Europe | 1,017 | 953 |
| Rest of world | 34,047 | 38,543 |
| 321,270 | 378,204 |
| Continuing operations | 2023 £000 |
2022 Restated £000 |
|---|---|---|
| Interest received on bank deposits | 627 | 319 |
| Foreign exchange gains on financing activities | 158 | 4,422 |
| Foreign exchange gains on operating activities | 4,709 | – |
| Cash flow hedges - ineffective portion of changes in fair value | 2,176 | – |
| Finance income | 7,670 | 4,741 |
| Leases (interest portion) | (1,620) | (1,580) |
| Cash flow hedges- re-classified from OCI | – | (2,546) |
| Cash flow hedges - in-effective portion of changes in fair value | – | (4,475) |
| Foreign exchange losses on operating activities | (4,547) | (1,620) |
| Interest expense on financial liabilities measured at amortised cost | (8,881) | (9,672) |
| Finance costs | (15,048) | (19,893) |
| Netfinance costsrecognised in profit or loss | (7,378) | (15,152) |
Items that are material because of their nature, non-recurring or whose significance is sufficient to warrant separate disclosure and identification within the consolidated financialstatements are referred to as exceptional items. The separate reporting of exceptional items helpsto provide an understanding of the Group's underlying performance.
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Acquisition related items | 652 | - |
| Exceptional restructuring costs | 3,470 | 1,229 |
| Disposal related items | (218) | (1,245) |
| Total exceptional items | 3,904 | (16) |
Acquisition related items comprise fees incurred in the year in connection with an aborted acquisition.
Exceptional costsinclude: £2,598,000 (2022: £843,000) of legal and professional costsin relation to preparing for listing the Group on the Oslo stock exchange, and £872,000 (2022: £276,000) relating to restructuring costs.
Disposal related items include a credit of £235,000 (2022: £1,203,000) in relation to additional contingent consideration received and receivable from disposalsin previous years(£294,000 relating to the disposal of Aquaculture UK on 7 February 2020, and £909,000 relating to the disposal of Improve International Limited and its subsidiaries on 23 June 2020) together with legal fees, lease costs and disposal items(net of proceedsreceived) totalling £17,000 relating to additional costs and disposals proceeds relating to disposals that occurred in 2020.
During the year, the group divested its tilapia business for consideration of USD 1 in a management buy out. Consequently, these operations have been classified as discontinued in the current year with a corresponding restatement of the consolidated income statement and OCI for the year ended 30 September 2022 to reflect these changes.
| Continuing operations | Discontinued operations |
|||
|---|---|---|---|---|
| Revenue £000 |
Adjusted EBITDA £000 |
Lossfrom continuing operations £000 |
Lossfrom discontinued operations £000 |
|
| Asstated in financial year 2022 financialstatements | 158,277 | 31,181 | (30,451) | - |
| Reclassified in financial year 2023 | (570) | 1,425 | 1,800 | (1,800) |
| Asstated in financial year 2023 financialstatements | 157,707 | 32,606 | (28,651) | (1,800) |
| Restated | ||
|---|---|---|
| 2023 £000 |
2022 £000 |
|
| Revenue | 268 | 570 |
| Cost ofsales | (973) | (1,372) |
| Gross profit | (705) | (802) |
| Research and development costs | (59) | (57) |
| Other operating costs | (490) | (566) |
| Adjusted EBITDA | (1,254) | (1,425) |
| Exceptional loss on disposal | (3,913) | - |
| EBITDA | (5,167) | (1,425) |
| Depreciation and impairment | (304) | (205) |
| Operating loss / Loss before taxation | (5,471) | (1,630) |
| Net finance costs | (34) | (164) |
| Loss before taxation | (5,505) | (1,794) |
| Tax on loss | - | (6) |
| Lossfrom discontinued operations | (5,505) | (1,800) |
| Total exceptional loss on disposal | 3,913 | – |
|---|---|---|
| Other costs relating to disposals | 139 | – |
| Loss on disposal of trade and assets | 3,774 | – |
| 2023 £000 |
Restated £000 |
|
| 2022 |
| 2023 | 2022 | |
|---|---|---|
| £000 | £000 | |
| Net cash flow from operating activities | (1,609) | (1,312) |
| Net cash flow from investing activities | (27) | (341) |
| Net cash flow from financing activities | (106) | 77 |
| Net cash flow from discontinued operations | (1,742) | (1,576) |
The results from discontinued operations relate solely to the Genetics operating segment.
| 2023 | 2023 | 2023 | |
|---|---|---|---|
| Continuing | Discontinued | Total | |
| £000 | £000 | £000 | |
| Revenue | 169,476 | 268 | 169,744 |
| Cost of sales | (82,726) | (973) | (83,699) |
| Gross profit | 86,750 | (705) | 86,045 |
| Research and development costs | (6,069) | (59) | (6,128) |
| Other operating costs | (45,157) | (490) | (45,647) |
| Share of profit of equity-accounted investees, net of tax | (32) | - | (32) |
| Adjusted EBITDA | 35,492 | (1,254) | 34,238 |
| Exceptional - restructuring, acquisition and disposal related items | (3,904) | (3,913) | (7,817) |
| EBITDA | 31,588 | (5,167) | 26,421 |
| Depreciation and impairment | (18,409) | (304) | (18,713) |
| Amortisation and impairment | (18,495) | - | (18,495) |
| Operating loss | (5,316) | (5,471) | (10,787) |
| Net finance costs | (7,378) | (34) | (7,412) |
| Loss before taxation | (12,694) | (5,505) | (18,199) |
|---|---|---|---|
| Tax on loss | (3,365) | - | (3,365) |
| Loss after tax for the financial period | (16,059) | (5,505) | (21,564) |
| 2022 Continuing |
2022 Discontinued |
2022 Total |
|
|---|---|---|---|
| Restated | Restated | Restated | |
| £000 | £000 | £000 | |
| Revenue | 157,707 | 570 | 158,277 |
| Cost of sales | (73,777) | (1,372) | (75,149) |
| Gross profit | 83,930 | (802) | 83,128 |
| Research and development costs | (6,634) | (57) | (6,691) |
| Other operating costs | (44,095) | (566) | (44,661) |
| Share of profit of equity-accounted investees, net of tax | (595) | - | (595) |
| Adjusted EBITDA | 32,606 | (1,425) | 31,181 |
| Exceptional - restructuring, acquisition and disposal related items | 16 | - | 16 |
| EBITDA | 32,622 | (1,425) | 31,197 |
| Depreciation and impairment | (19,692) | (205) | (19,897) |
| Amortisation and impairment | (19,161) | - | (19,161) |
| Operating loss | (6,231) | (1,630) | (7,861) |
| Net finance costs | (15,152) | (164) | (15,316) |
| Loss before taxation | (21,383) | (1,794) | (23,177) |
| Tax on loss | (7,268) | (6) | (7,274) |
| Loss after tax for the financial period | (28,651) | (1,800) | (30,451) |
On 30 September, the tilapia businesses of a Group's subsidiary was disposed of for consideration of USD 1. The assets sold are highlighted in the table below.
| Tilapia |
|---|
| £000 |
| 738 |
| 3,036 |
| 3,774 |
| – |
| – |
| – |
| – |
Basic loss per share is calculated by dividing the profit orloss attributable to ordinary equity holders ofthe Company by the weighted average number of ordinary shares in issue during the period.
| 2023 | 2022 | |||||
|---|---|---|---|---|---|---|
| Continuing | Discontinued | Total | Continuing | Discontinued | Total | |
| Loss attributable to equity holders of the parent (£000) | (17,641) | (5,505) | (23,146) | (30,287) | (1,800) | (32,087) |
| Weighted average number of shares in issue (thousands) | 731,935 | 698,233 | ||||
| Basic loss per share (pence) | (2.41) | (0.75) | (3.16) | (4.34) | (0.26) | (4.60) |
Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. This is done by calculating the number of shares that could have been acquired at fair value based on the monetary value of the subscription rights attached to outstanding share options and warrants.
A total of 8,948,132 (2022: 6,240,304) potential ordinary shares have not been included within the calculation of statutory diluted loss per share for the year as they are anti-dilutive and reduce the loss per share. However, these potential ordinary shares could dilute earnings per share in the future. The diluted and basic loss per share are the same for both continuing and discontinued.
| Freehold Land and Buildings £000 |
Assets in the course of construction £000 |
Long-Term Leasehold Property Improvements £000 |
Plant and Machinery £000 |
Office Equipment and Fixtures £000 |
Total £000 |
|
|---|---|---|---|---|---|---|
| Cost | ||||||
| Balance at 1 October 2021 | 63,027 | 1,807 | 6,421 | 32,893 | 2,751 | 106,899 |
| Additions | 4,025 | 1,616 | 283 | 4,546 | 338 | 10,808 |
| Increase/(decrease) through transfersfrom assets in the course of construction |
251 | (1,275) | – | 995 | 29 | – |
| Exchange differences | 1,924 | 116 | 432 | 2,377 | 146 | 4,995 |
| Transfer to inventory | – | – | – | (1,514) | – | (1,514) |
| Disposals | (224) | – | – | (131) | (126) | (481) |
| Disposals through sale of subsidiary | – | – | – | – | – | – |
| Balance at 30 September 2022 | 69,003 | 2,264 | 7,136 | 39,166 | 3,138 | 120,707 |
| Balance at 1 October 2022 | 69,003 | 2,264 | 7,136 | 39,166 | 3,138 | 120,707 |
| Additions | 2,164 | 560 | 28 | 2,662 | 539 | 5,953 |
| On acquisition | – | – | – | 315 | – | 315 |
| Reclassification | 56 | (106) | – | 50 | – | – |
| Increase/(decrease) through transfers from | ||||||
| assetsin the course of construction | 877 | (1,556) | – | 679 | – | – |
| Exchange differences | (4,446) | (53) | (344) | (1,670) | (328) | (6,841) |
| Transfer to assets held for sale | (1,392) | – | – | – | – | (1,392) |
| Transfer from inventory | – | – | – | 94 | – | 94 |
| Balance at 30 September 2023 | 66,181 | 1,109 | 5,245 | 39,175 | 3,291 | 115,001 |
| Accumulated depreciation | ||||||
| Balance at 1 October 2022 | 7,829 | – | 4,723 | 14,806 | 761 | 28,119 |
| Depreciation charge for the year | 2,387 | – | 197 | 5,411 | 607 | 8,602 |
| Exchange differences | 792 | – | 256 | 1,200 | 141 | 2,389 |
| Disposals | (84) | – | – | (102) | (117) | (303) |
| Balance at 30 September 2022 | 10,924 | – | 5,176 | 21,315 | 1,392 | 38,807 |
| Balance at 1 October 2022 | 10,924 | – | 5,176 | 21,315 | 1,392 | 38,807 |
| Depreciation charge for the year | 2,266 | – | 79 | 5,513 | 595 | 8,453 |
| Transfer to assets held for sale | (542) | – | – | – | – | (542) |
| Exchange differences | (908) | – | (189) | (810) | (214) | (2,121) |
| Disposals | (81) | – | (1,575) | (1,323) | (28) | (3,007) |
| Balance at 30 September 2023 | 11,659 | – | 3,491 | 24,695 | 1,745 | 41,590 |
| Net book value | ||||||
| At 30 September 2023 | 54,522 | 1,109 | 1,754 | 14,480 | 1,546 | 73,411 |
| At 30 September 2022 | 58,079 | 2,264 | 1,960 | 17,851 | 1,746 | 81,900 |
| At 1 October 2021 | 55,198 | 1,807 | 1,698 | 18,087 | 1,990 | 78,780 |
| Group | ||
|---|---|---|
| Right-of-use-assets | 2023 £000 |
2022 £000 |
| Leasehold property | 9,213 | 9,389 |
| Plant and machinery | 10,585 | 17,582 |
| Office equipment and fixtures | 6 | 63 |
| 19,804 | 27,034 | |
| Lease liabilities | 2023 £000 |
2022 £000 |
| Current | 11,567 | 11,522 |
| Non-current | 8,293 | 14,765 |
| 19,860 | 26,287 | |
| Depreciation charge of right-of-use assets | 2023 £000 |
2022 £000 |
| Leasehold property | 1,210 | 1,383 |
| Plant and machinery | 9,038 | 9,176 |
| Office equipment and fixtures | 12 | 72 |
| 10,260 | 10,631 | |
| Additional information | 2021 £000 |
2020 £000 |
| Additionsto right-of-use assets | 2,120 | 497 |
| Modificationsto right-of-use assets | 1,697 | 10,884 |
| Impairment of leasehold property right-of-use asset | – | 664 |
| Interest expense | 1,654 | 1,744 |
| Expense relating to short-term leases | 237 | 152 |
| Expense relating to leases of low-value leases | 20 | 151 |
| Total cash outflow for leases | 9,438 | 10,533 |
Benchmark Animal Health Limited modified the existing leasesfor two PSV vessels, the FS Aquarius and the FS Pegasusto extend the lease term only. These two assets constitute £8,405,000 of the net book value and £9,374,000 of the lease liability at the year end.
| Websites £000 |
Goodwill £000 |
Patents and Trademarks £000 |
Intellectual Property £000 |
Customer Lists £000 |
Contracts £000 |
Licences £000 |
Genetics £000 |
Development costs £000 |
Total £000 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Cost or valuation | ||||||||||
| Balance at 1 October 2021 | 319 | 140,055 | 338 | 133,201 | 5,271 | 6,602 | 34,479 | 22,636 | 27,579 | 370,480 |
| Additions - externally acquired |
94 | – | 111 | – | – | – | – | – | – | 205 |
| Additions- internally developed |
– | – | – | – | – | – | – | – | 1,708 | 1,708 |
| Exchange differences | 34 | 24,619 | 3 | 27,206 | 1,107 | (27) | 5,841 | 599 | 1,935 | 61,317 |
| Balance at 30 September 2022 |
447 | 164,674 | 452 | 160,407 | 6,378 | 6,575 | 40,320 | 23,235 | 31,222 | 433,710 |
| Balance at 1 October 2022 | 447 | 164,674 | 452 | 160,407 | 6,378 | 6,575 | 40,320 | 23,235 | 31,222 | 433,710 |
| Additions- on acquisition | – | – | – | – | – | – | – | – | – | – |
| Additions – externally acquired | 80 | 1 | 115 | – | – | – | – | – | – | 196 |
| Additions – internally developed | – | – | – | – | – | – | – | – | 632 | 632 |
| Disposals | – | (3,036) | (21) | – | – | – | (150) | – | – | (3,207) |
| Reclassification to assets held for resale |
– | – | – | – | – | – | – | – | – | – |
| Exchange differences | (15) | (13,682) | (1) | (13,737) | (559) | (70) | (3,186) | (1,267) | (982) | (33,499) |
| Balance at 30 September 2023 |
512 | 147,957 | 545 | 146,670 | 5,819 | 6,505 | 36,984 | 21,968 | 30,872 | 397,832 |
| Accumulated amortisation and impairment |
||||||||||
| Balance at 1 October 2021 | 67 | 41,358 | 133 | 73,541 | 1,166 | 6,210 | 13,077 | 4,111 | 1,777 | 141,440 |
| Amortisation charge for the period |
67 | – | 70 | 13,574 | 215 | 102 | 2,027 | 636 | 2,165 | 18,856 |
| Impairment | – | – | – | 305 | – | – | – | – | – | 305 |
| Exchange differences | 9 | 8,592 | 3 | 16,966 | 275 | (19) | 1,839 | 139 | 41 | 27,845 |
| Balance at 30 September 2022 |
143 | 49,950 | 206 | 104,386 | 1,656 | 6,293 | 16,943 | 4,886 | 3,983 | 188,446 |
| Balance at 1 October 2022 | 143 | 49,950 | 206 | 104,386 | 1,656 | 6,293 | 16,943 | 4,886 | 3,983 | 188,446 |
| Amortisation charge for the period |
85 | – | 91 | 12,605 | 222 | 94 | 1,818 | 606 | 2,437 | 17,958 |
| Impairment | – | 1 | – | 61 | – | – | 476 | – | – | 538 |
| Disposals | – | – | (21) | – | – | – | (150) | – | – | (171) |
| Exchange differences | (4) | (4,484) | (2) | (8,868) | (143) | (52) | (1,177) | (253) | (33) | (15,016) |
| Balance at 30 September 2023 |
224 | 45,467 | 274 | 108,184 | 1,735 | 6,335 | 17,910 | 5,239 | 6,387 | 191,755 |
| Net book value | ||||||||||
| At 30 September 2023 | 288 | 102,490 | 271 | 38,486 | 4,084 | 170 | 19,074 | 16,729 | 24,485 | 206,077 |
| At 30 September 2022 | 304 | 114,724 | 246 | 56,021 | 4,722 | 282 | 23,377 | 18,349 | 27,239 | 245,264 |
| At 1 October 2021 | 252 | 98,697 | 205 | 59,660 | 4,105 | 392 | 21,402 | 18,525 | 25,802 | 229,040 |
The table below provides further detail of intangibles and their remaining amortisation period.
| Description | Category | NBV 2023 £000 |
NBV 2022 £000 |
Remaining life 2023 |
|---|---|---|---|---|
| Acquisition of INVE in 2015 | ||||
| Goodwill | Goodwill | 79,909 | 87,585 | – |
| Harvesting rights | Licences | 19,029 | 22,449 | 12 |
| Product technology | Intellectual property | – | 446 | – |
| Product rights | Intellectual property | 24,880 | 39,390 | 2 |
| Brand names | Intellectual property | 10,945 | 12,976 | 12 |
| In-process R&D | Intellectual property | 535 | 847 | 2 |
| Customer relationships | Customer lists | 4,085 | 4,723 | 18 |
| Total relating to acquisition of INVE | 139,383 | 168,416 | – | |
| Acquisition of Salmobreed AS (Now part of Benchmark Genetics Norway AS) in 2014 |
||||
| Goodwill | Goodwill | 6,063 | 6,523 | – |
| Genetic material and breeding nuclei | Genetics | 8,926 | 9,911 | 31 |
| Total relating to acquisition of Salmobreed AS | 14,989 | 16,434 | – | |
| Acquisition of Stofnfiskur( Now Benchmark Genetics Iceland) in 2014 |
||||
| Goodwill | Goodwill | 11,999 | 12,467 | – |
| Genetic material and breeding nuclei | Genetics | 7,598 | 8,147 | 31 |
| Total relating to acquisition of Stofnfiskur | 19,597 | 20,614 | – | |
| Acquisition of Akvaforsk Genetics Center AS (Now part of | ||||
| Benchmark Genetics Norway AS) in 2015 | ||||
| Goodwill | Goodwill | 4,520 | 7,348 | – |
| Licences | Licences | – | 292 | – |
| Contracts | Contracts | 170 | 282 | 2 |
| Total relating to acquisition of Akvaforsk Genetics Center AS | 4,690 | 7,922 | – | |
| Capitalised development costs | ||||
| Ectosan®Vet/CleanTreat® | Development costs | 14,048 | 15,840 | 8 Not yet ready |
| Live food alternative diets | Development costs | 3,879 | 4,115 | for use |
| SPR Shrimp | Development costs | 5,453 | 6,686 | 8 |
| Total capitalised development costs | 23,380 | 26,641 | ||
| Other purchased material intangible assets | Intellectual Property | 1,408 | 1,497 | 16 |
| Total relating to other purchased intangible assets | 1,408 | 1,497 | ||
| Other individually immaterial goodwill and intangibles | 2,630 | 3,740 | ||
| Total net book value at 30 September | 206,077 | 245,264 |
The Group tests goodwill and other intangibles not yet ready for use annually for impairment, or more frequently if there are indications that goodwill or the other intangible assets might be impaired. Goodwill acquired in a business combination is allocated, at acquisition, to the cash generating units (CGUs) that are expected to benefit from the business combination. The only intangible assets not yet ready for use are generally the capitalised development costs on internally developed products. The development costs included in the table below represents only those that are not yet ready for use.
Due to the interdependence of the operations within each of the business areas and the way in which they are managed, management have determined the CGUs are the business areas themselves – Health, Genetics and Advanced Nutrition. These are the smallest groups of assets that independently generate cashflows and whose cashflows are largely independent of those generated by other assets. Goodwill and capitalised development costs arise across the Group, and are allocated specifically against the CGUs as follows:
| Advanced | |||
|---|---|---|---|
| Genetics | Nutrition | Total | |
| 2023 | 2023 | 2023 | |
| £000 | £000 | £000 | |
| Benchmark Genetics AS | 6,062 | – | 6,062 |
| Benchmark Genetics Iceland HF (Previously Stofnfiskur HF) | 11,999 | – | 11,999 |
| Akvaforsk Genetic Center* | 4,520 | – | 4,520 |
| INVE Aquaculture Group | – | 79,909 | 79,909 |
| Goodwill | 22,581 | 79,909 | 102,490 |
| Development costs | – | 3,879 | 3,879 |
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics Center AS (which was transferred into Benchmark Genetics Norway AS) and Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
| Genetics 2022 £000 |
Advanced Nutrition 2022 £000 |
Total 2022 £000 |
|
|---|---|---|---|
| Benchmark Genetics AS | 6,522 | – | 6,522 |
| Benchmark GeneticsIceland HF (Previously Stofnfiskur HF) | 12,467 | – | 12,467 |
| Akvaforsk Genetic Center* | 8,150 | – | 8,150 |
| INVE Aquaculture Group | – | 87,585 | 87,585 |
| Goodwill | 27,139 | 87,585 | 114,724 |
| Development costs | – | 4,115 | 4,115 |
* Includes goodwill arising from the joint acquisition of Akvaforsk Genetics Center AS (which was transferred into Benchmark Genetics Norway AS) and Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).
The recoverable amounts of the above CGUs have been determined from value-in-use calculations. These calculations used Board approved cash flow projections from five-year business plans based on actual operating results and current forecasts. These forecasts were then extrapolated into perpetuity taking account of specific terminal growth rates for future cash flows, using individual business operating margins based on past experience and future expectations in light of anticipated economic and market conditions. The pre-tax cash flows that these projections produced were discounted at pre-tax discount rates based on the Group's beta adjusted cost of capital, further adjusted to reflect management's assessment of specific risks related to the markets and other factors pertaining to each CGU. Forecasts also include any costs in relation to the Group's climate change strategy and climate change factors have been considered when setting the long-term growth rates.
The values assigned to the key assumptions represent management's assessment of future trends in the relevant industries and have been based on historical data from both external and internal sources.
The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 15.7% (2022: 14.7%). CAGR of revenue of 9% (2022: 15%) is implied by the five-year plan and a long-term growth rate of 2.5% (2022: 2.5%) has been used to extrapolate the terminal year cashflow into perpetuity.
Having conducted a sensitivity analysis of key assumptions, no reasonably possible changes that would result in the elimination of all headroom were identified.
The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 16.4% (2022: 15.6%). CAGR of revenue of 12% (2022: 10%) is implied by the five-year plan and a long-term growth rate of 3.5% (2022: 3.5%) has been used to extrapolate the terminal year cashflow into perpetuity. Market analysis reports predict long-term growth rates of c.5.0%, and the health benefits of shrimp are still very much in evidence. Management believes that a long-term growth rate of 3.5% represents both a prudent and consistent approach for the CGU.
Sensitivity analysis has been performed on the key assumptions. Reducing the forecast growth rates for less mature parts of the CGU within Health and Diets products did not result in elimination of headroom. However, the forecasts growth rates for the CGU include an assumption around the ongoing recovery in global shrimp markets, and if that recovery is slower than the forecasts anticipate, due to factors such as continued reduced end market demand for Shrimp, to the extent that the CAGR of revenue implied over the five-year plan falls to 9%, this would result in a potential impairment.
The sensitivity to movements in the terminal growth rate and discount rate were also assessed, and a reduction in terminal growth rate from 3.5% to 1.5%, or an increase in the discount rate from 16.4% to 18.4%, either of which are considered to be reasonably possible, would reduce the headroom on the Advanced Nutrition CGU of £31.6m to nil. Should the growth rate reduce or discount rate increase further than this, then an impairment would be likely.
The pre-tax cashflows from the five-year projections were discounted using a pre-tax discount rate of 17.4% (2022: 16.4%). An assumed CAGR of revenue of 23% (2022: 27%) in the five-year plan reflects the importance of the successful commercial ramp- up of the business area's new sea lice treatment in the forecast period. A long-term growth rate of 0.0% (2022: 0.0%) has been used to extrapolate the terminal year cashflow into perpetuity. The prudent assumption in the long-term growth rate is intended to reflect that the business area's new sea lice treatment is the principal source of cash generation, and only benefits from patent protection against generic competitors for a finite period of time.
The valuation of the Health cash generating unit indicates sufficient headroom such that a reasonably possible change to key assumptions is unlikely to result in an impairment in related development costs.
| Group | 2023 £000 |
2022 £000 |
|---|---|---|
| Salmon eggs | 10,631 | 14,037 |
| Salmon broodstock | 33,411 | 30,501 |
| Salmon milt | 796 | 606 |
| Lumpfish fingerlings | 757 | 1,090 |
| Shrimp | 397 | 424 |
| Total biological assets 30 September | 45,992 | 46,658 |
| Analysed as | ||
| Current | 27,586 | 25,780 |
| Non-current | 18,406 | 20,878 |
| Total biological assets 30 September | 45,992 | 46,658 |
| 2023 | 2022 | |
|---|---|---|
| £000 | £000 | |
| Biological assets 1 October Increase | 46,658 | 38,365 |
| Increase from production | 42,393 | 48,067 |
| Reduction due to sales | (40,583) | (45,535) |
| Other movements in biological assets | 1,810 | 4,532 |
| Foreign exchange movement before fair value adjustment | (1,562) | 1,704 |
| Change in fair value through income statement | (103) | 1,595 |
| Foreign exchange impact on fair value adjustment | (811) | 462 |
| Biological assets 30 September | 45,992 | 46,658 |
IAS 41 requires that biological assets are accounted for at the estimated fair value net of selling and harvesting costs. Fair value is measured in accordance with IFRS 13 and is categorised into levels in the fair value hierarchy.
The fair value inputs for salmon eggs are categorised as level 2. The calculation of the fair value of the salmon eggs is based upon the current seasonally adjusted selling prices for salmon eggs less transport and incubation costs and taking account of the market capacity. The valuation also takes account of the mortality rates of the eggs and expected life as sourced from internally generated data.
The fair value inputs for salmon broodstock are categorised as level 3. The broodstock contain generations of genetic improvements and cannot be valued purely on the market weight of salmon. The Group does not sell its broodstock commercially so there is no observable input in this respect. Therefore, the calculation of the estimated fair value of salmon broodstock is primarily based upon its main harvest output being salmon eggs, which are priced upon the current seasonally adjusted selling prices for the Group's salmon eggs. These prices are reduced for harvesting costs, freight costs, incubation costs and market capacity to arrive at the net value of broodstock. The valuation also reflects the internally generated data to arrive at the biomass.
This includes the weight of the broodstock, the yield that each kilogram of fish will produce and mortality rates. The fish take four years to reach maturity, and the age and biomass of the fish is taken into account in the fair value. Finally, the valuation takes account of future expected sales volumes.
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Biological assets 1 October | 30,501 | 26,700 |
| Increase from production | 25,494 | 28,720 |
| Transfer to salmon eggs following harvesting | (22,677) | (26,509) |
| Foreign exchange movement before fair value adjustment | (1,199) | 1,326 |
| Change in fair value through income statement | 1,853 | (31) |
| Foreign exchange impact on fair value adjustment | (561) | 295 |
| Biological assets 30 September | 33,411 | 30,501 |
| Significant unobservable inputs used in the valuation of salmon broodstock | ||
| 2023 | 2022 | |
| Number of eggs valued in broodstock (m units) | 250 | 222 |
|---|---|---|
| Average selling price per egg (GBP) | 0.131 | 0.135 |
| Future costs per egg (GBP) | (0.016) | (0.021) |
The fair value inputs for lumpfish fingerlings and shrimp are categorised as level 2. The calculation of the fair value of lumpfish fingerlings and shrimp is valued on current selling prices less transport costs. Internally generated data is used to incorporate mortality rates and the weight of the biomass.
The fair value inputs for lumpfish fingerlings and shrimp are categorised as level 2. The calculation of the fair value of lumpfish fingerlings and shrimp is valued on current selling prices less transport costs. Internally generated data is used to incorporate mortality rates and the weight of the biomass.
The fair value inputs for salmon milt are categorised as level 3. Where we have identified individual salmon carrying particular traits or disease resistance, semen (milt) can be extracted and deep-frozen using cryopreservation techniques (the process of freezing biological material at extreme temperatures in liquid nitrogen). The calculation of the fair value of milt is based on production and freezing costs and, where appropriate, an uplift to recognise the additional selling price that can be achieved from eggs fertilised by premium quality milt.
There is a presumption that fair value can be measured reliably for a biological asset. However, we sometimes face a situation where alternative estimates of fair value are determined to be clearly unreliable (for example, where we establish a new broodstock farm in a new territory). In such a case, that biological asset shall be measured at its cost less any accumulated impairment losses. In the year this applied to £2,150,000 of broodstock in Chile. As at 30 September the gross carrying amount was £5,186,000 (2022: £4,704,000) and the accumulated impairment losses were £3,036,000 (2022: £2,735,000).The valuation models by their nature are based upon uncertain assumptions on sales prices, market capacity, weight, mortality rates, yields and assessment of the discounts to reflect the stages of maturity. The Group has a degree of expertise in these assumptions but these assumptions are subject to change. Relatively small changes in assumptions would have a significant impact on the valuation. A 1% increase/decrease in the assumed selling price per egg would increase/decrease the fair value of salmon broodstock and eggs by £440,000. A 10% increase/decrease in the biomass of salmon broodstock and the quantity of salmon eggs valued would increase/decrease the fair value of those biological assets by £4,404,000.
The Group is exposed to financial risks arising from changes in the market value of the salmon eggs, lumpfish fingerlings and shrimp broodstock that it sells. The Group does not anticipate that prices will decline significantly in the foreseeable future and, therefore, has not entered into derivative or other contracts to manage the risk of a decline in the price of its products. The Group reviews its outlook for salmon eggs, lumpfish fingerlings and shrimp broodstock prices regularly in considering the need for active financial risk management.
The Group is exposed to the following risks relating to its aquaculture activities. These risks and management's strategies to mitigate them are described below:
The nature of certain of the Group's operating activities exposes us to certain significant risks to the environment, such as incidents associated with releases of chemicals or hazardous substances when conducting our operations, which could result in liability, fines, risk to our product permissions and reputational damage. There is a risk that natural disasters could lead to damage to infrastructure, loss of resources, products or containment of hazardous substances. Our business activities could be disrupted if we do not respond, or are perceived not to respond, in an appropriate manner to any major crisis or if we are not able to restore or replace critical operational capacity.
In mitigation we have implemented standards and requirements which govern key risk management activities such as inspection, maintenance, testing, business continuity and crisis response.
The Group is exposed to the risk of disease within the Group's own operations and disease in the market resulting in possible border closures. In mitigation, the Group:
Total output of aquaculture activity in the year was:
| 2023 | 2022 | |
|---|---|---|
| Salmon eggs | 334.7m units | 291.1m units |
| Lumpfish fingerlings | 1.5m units | 2.0m units |
| Total quantities held at 30 September were: | 2023 | 2022 |
| Salmon eggs | 85.6m units | 103.9m units |
| Salmon broodstock | 1,517 tonnes | 1,737 tonnes |
| Lumpfish fingerlings | 0.4m units | 0.7m units |
| Group | 2023 £000 |
2022 £000 |
|---|---|---|
| Trade receivables | 27,460 | 31,218 |
| Less: provision for impairment of trade receivables | (2,612) | (2,748) |
| Trade receivables – net | 24,848 | 28,470 |
| Total financial assets other than cash and cash equivalents measured at amortised cost | 24,848 | 28,470 |
| Other receivables- contingent consideration | – | 887 |
| Total financial assets other than cash and cash equivalents classified as measured at fair value through | ||
| profit and loss | – | 887 |
| Prepayments | 18,081 | 14,989 |
| Other receivables | 16,866 | 12,031 |
| Total trade and other receivables | 59,795 | 56,377 |
Other receivables relate to the following items: VAT recoverable £4,353,000 (2022: £4,386,000), research and development expenditure tax credits and similar items £157,000 (2022: £154,000), the right to receive an agreed proportion of a key supplier's harvest* £10,173,000 (2022: £5,249,200), accrued income of £1,177,000 (2022: £1,377,000) and other amounts receivable of £1,006,000 (2022: £865,000).
*A financial liability of £10,173,000 (2022: £5,249,200) is recognised (within trade payables) for the amount invoiced and remaining outstanding at the year-end in relation to the Group's contractual obligation to pay for a specified share of the harvest of a supplier, regardless of delivery and without recourse to the supplier. As at 30 September, as the Group has not taken physical delivery of the harvested product and as the Group does not control the harvested product, an 'other receivable' of £10,173,000 (2022: £5,249,200) has been recorded in relation to the Group's right to receive the product in the future.
The financial asset at fair value through profit and loss related to contingent consideration outstanding from the disposal of Improve International Limited in FY20. This related to deferred cash consideration dependent on the delivery of certain future revenues in the financial year ended 30 September 2022 and the fair value was derived from the likely receivable amount based on expectations of performance against the targets. The amount recovered in the financial year ended 30 September 2023 was not materially different to management's estimate.
The fair values of trade and other receivables measured at amortised cost are not materially different to their carrying values. As at 30 September 2023 trade receivables of £6,313,000 (2022: £5,943,000) were past due but not impaired. They relate to customers with no default history. The ageing analysis of these receivables is as follows:
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Up to 3 months overdue | 5,480 | 5,761 |
| 3 to 6 months overdue | 833 | 218 |
| 6 to 12 months overdue | – | (36) |
| 6,313 | 5,943 |
Movements on the Group provision for impairment of trade receivables are as follows:
| 2023 £000 |
2023 £000 |
|
|---|---|---|
| At 1 October | 2,748 | 2,493 |
| Provided during the year | 696 | 281 |
| Unused provisionsreversed | (600) | (180) |
| Provisions used during the year | (32) | – |
| Foreign exchange movements | (200) | 154 |
| At 30 September | 2,612 | 2,748 |
The movement on the provision for impaired receivables has been included in the operating costs line in the Consolidated Income Statement.
Other classes of financial assets included within trade and other receivables do not contain impaired assets.
| Group | 2023 £000 |
2022 £000 |
|---|---|---|
| Trade payables | 26,657 | 22,149 |
| Other payables | 2,213 | 1,127 |
| Accruals | 16,257 | 17,636 |
| Other payables - tax and socialsecurity payments | 2,957 | 3,799 |
| Financial liabilities, excluding loans and borrowings, classified asfinancial liabilities measured at amortised cost |
48,084 | 44,711 |
| Financial contracts - hedging instrument | 5,683 | 8,012 |
| Financial liabilities, excluding loans and borrowings, classified asfinancial liabilities at fair value through profit or loss |
5,683 | 8,012 |
| Deferred income | 404 | 597 |
| Total trade and other payables | 54,171 | 53,320 |
| Less: non-current portion of other payables | (6,842) | (8,996) |
| Current portion | 47,329 | 44,324 |
Book values approximate to fair value at 30 September 2023 and 2022.
Of the financial contracts £6,155,000 (2022: £8,387,000) relates to a NOKUSD floating to fixed cross-currency interest rate swap (CCS) and a NOK interest rate swap (IRS), both of which were entered to fully match the timing and tenor of the underlying new senior unsecured floating rate listed bond issue of NOK 750m.
The floating-to-fixed NOK IRS (notional NOK 300m) is designated a cash flow hedge where any changes in the fair value of the swap will be taken directly to equity within the hedging reserve and recycled to profit or loss as the bond impacts the profit or loss.
The NOKUSD CCS (notional NOK450m) has been separated into two synthetic swaps; the first is a floating-to-fixed NOKGBP interest rate swap, being a cash flow hedge of the foreign exchange and interest rate risk on NOK denominated debt. The fair value of this synthetic swap is posted to the hedging reserve in equity. The second synthetic swap is a fixed-to-fixed GBPUSD swap designated as a net investment hedge in the USD net assets in the consolidated accounts of Benchmark Holdings plc. The fair value of this leg is posted to the foreign exchange translation reserve in equity.
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Non-Current | ||
| 2025 750m NOK Loan notes | 57,604 | 61,976 |
| Bank borrowings | 16,799 | 17,226 |
| Unamortised debt issue costs | (742) | (922) |
| Lease liabilities | 8,293 | 14,765 |
| 81,954 | 93,045 | |
| Current | ||
| Bank borrowings | 9,320 | 5,569 |
| Unamortised debt issue costs | (842) | – |
| Lease liabilities | 11,567 | 11,522 |
| 20,045 | 17,091 | |
| Total loans and borrowings | 101,999 | 110,136 |
At 30 September 2023 the fair value of the unsecured floating rate listed green bond of NOK 750m was NOK 791m.
On 21 November 2022, the Group refinanced its USD15m RCF with a secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the leverage of the Group above the relevant risk free reference or IBOR rates depending on which currency is drawn.
Benchmark Genetics Salten AS had the following loans (which are ring-fenced debt without recourse to the remainder of the Group) at 30 September 2023:
The lease liabilities are secured on the assets to which they relate.
The currency profile of the Group's loans and borrowings is as follows:
| 2023 £000 |
2022 £000 |
|
|---|---|---|
| Sterling | 16,680 | 19,697 |
| Norwegian Krone | 76,730 | 81,634 |
| Thai Baht | 464 | 954 |
| Euro | 614 | 272 |
| US Dollar | 6,460 | 6,888 |
| Icelandic Krone | 585 | 545 |
| Other | 466 | 146 |
| 101,999 | 110,136 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.